

NOVEL NOR-PREGNANES FOR INDUCING HYPOTHALAMIC EFFECTS

5 Cross Reference To Related Applications

This application is related to U.S. Application Serial No. 08/127,908, filed September 28, 1993 which is a continuation-in-part of U.S. Application Serial No. 07/903,604, filed 24 June 1992, which in turn is a
10 continuation-in-part of U.S. Application Serial No. 07/708,936, filed 31 May 1991, which in turn is a continuation-in-part of U.S. Application Serial No. 07/638,185, filed 7 January 1991, now abandoned.

The application also relates to U.S. Application
15 Serial No. 08/127,980 filed September 28, 1993 which is another continuation-in-part of U.S. Patent Application Serial No. 07/903,604, U.S. Patent Application Serial No. 08/077,359, filed 15 June 1993, and to commonly assigned, co-pending U.S. Patent Application Serial No. 07/903,525,
20 filed 24 June 1992 (a continuation-in-part of U.S. Application Serial No. 07/707,862, filed 31 May 1991, which in turn is a continuation in-part of U.S. Application Serial No. 07/638,743, filed 7 January 1991, now abandoned) entitled "Estrene Steroids as
25 Neurochemical Initiators of Change in Human Hypothalamic Function and Related Pharmaceutical Compositions and Methods"; and to the commonly assigned, co-pending continuation-in-part of 07/903,525, U.S. Patent Application Serial No. 08/077,140. The aforementioned
30 U.S. patent applications are each incorporated herein by reference.

Finally, this application may relate to U.S. Patent Application entitled "Fragrance Compositions Containing Human Pheromones, filed 24 March 1992,
35 U.S.S.N. 07/856,435.

Technical Field

This invention relates generally to pharmaceutical compositions and methods for effectuating change in human hypothalamic function, thereby altering certain behavior and physiology mediated by the hypothalamus of individuals. More particularly, the invention relates to the use of 19-nor-pregnane steroids as neurochemical effectuators of physiology and behavior.

Description of the Related Art

The present invention relates to certain compounds, namely 19-norpregnane steroids, particularly 19-norpregnane steroids and related compounds as will be described herein, and methods of using these compounds as human vomeropherins in order to alter hypothalamic function, thereby affecting certain consequent behavior and physiology, e.g., the reduction of anxiety. The 19-nor-pregnane steroids are characterized by a four ring steroidal structure, methylation at the 13 position and ethylation at the 17-position. The 19-nor-pregnenes are a subset which have at least one double bond.

Ohloff, G. et al. (Helv. Chim. Acta (1983) 66:192-217), which is incorporated herein by reference, have shown that several steroids (androstenes) have an odor which varies with different isomeric, diastereomeric, and enantiomeric forms. Some members of this group have been reported to act as a pheromone in some mammalian species for instance, 5 α -androst-16-en-3-one and 5 α -androst-16-en-3 α -ol in pigs (Melrose, D.R., et al., Br. vet. J. (1971) 127:497-502). These 16-androstenes produced by the boar induce mating behavior in estrus sows (Claus, et al., Experimentia (1979) 35:1674-1675).

In some studies it has been noted that, in some

species, various characteristics of certain 16-androstenes (including 5 α -Androst-16-en-3 α -ol and 5 α -Androst-16-en-3-one), such as concentration, metabolism, and localization, are sexually dimorphic

5 (Brooksbank et al., J. Endocr. (1972) 52:239-251; Claus, et al., J. Endocr. (1976) 68:483-484; Rwan, et al., Med. Sci. Res. (1987) 15:1443-1444). For instance, 5 α -Androst-16-en-3 α -ol and 5 α -Androst-16-en-3-one, as well as Androsta-4,16-dien-3-one, have been found at

10 different concentrations in the peripheral blood, saliva and axillary secretions of men and of women (Kwan, T.X., et al., Med. Sci. Res. (1987) 15:1443-1444), and their function as a human pheromone, to the extent of affecting choice and judgement, has been suggested (Id.; see also

15 Gower, et al., "The Significance of Odorous Steroids in Axillary Odour", In, Perfumery, pp. 68-72, Van Toller and Dodd, Eds., Chapman and Hall, 1988); Kirk-Smith, D.A., et al., Res. Comm. Psychol. Psychiat. Behav. (1978) 3:379). Androstenol (5 α -androst-16-en-3 α -ol) has been claimed to

20 exhibit a pheromone-like activity in a commercial men's cologne and women's perfume (Andron for men and Andron for women by Jovan). Japanese Kokai No. 2295916, refers to perfume compositions containing androstenol and/or its analogues. 5 α -Androstadien-3 β -ol (and perhaps the 3 α -ol)

25 has also been identified in human axillary secretion (Gower, et al., Supra at 57-60. On the other hand, there is little agreement in the literature as to whether or not any putative pheromone actually plays any role in the sexual or reproductive behavior of mammals, particularly

30 of humans. See: Beauchamp, G.X., et al., "The Pheromone Concept in Mammalian Chemical Communication: A Critique", In: Mammalian Olfaction. Reproductive Processes and Behavior, Doty R.L., Ed., Academic Press, 1976). See also: Gower, et al., supra at 68-73.

35 The pheromone properties of some estrene steroids

for some mammalian species have been described. Michael, R.P. et al., Nature (1968) 218:746 refers to Estrogens (particularly Estradiol) as a pheromonal attractant of male rhesus monkeys. Parrot, R.F., Hormones and Behavior 5 (1976) 7:207-215, reports Estradiol benzoate injection induces mating behavior in ovariectomized rats; and the role of the blood level of Estradiol in male sexual response (Phoenix, C.H., Physiol. and Behavior (1976) 16:305-310) and female sexual response (Phoenix, C.H., 10 Hormones and Behavior (1977) 8:356-362) in Rhesus monkeys has been described. On the other hand, there is little agreement in the literature as to whether or not pheromones as such play any role in the reproductive behavior and interpersonal communication of mammals 15 (Beuchamp, G.K., et al., "The Pheromone Concept in Mammalian Chemical Communication: A Critique", In: Mammalian Olfaction Reproductive Processes. and Behavior, Doty, R.L., Ed., Academic Press, 1976).

An embodiment of the subject invention concerns 20 the non-systemic, nasal administration of certain 19-nor-pregnane and 19-nor-pregnene steroids to affect a specific behavioral or physiological response in human subjects, e.g., a reduction of negative affect, mood, and character traits. In particular, nasal administration 25 provides for contacting neurochemical receptors of a heretofore poorly understood neuroendocrine structure, commonly known as the vomeronasal organ ("VNO"; also known as "Jacobson's organ"), with one or more steroid(s) or with compositions containing the steroid(s). This 30 organ is accessed through the nostrils of most higher animals - from snakes to humans, and has been associated, inter alia, with pheromone reception in certain species (see generally Muller-Schwarze & Silverstein, Chemical Signals, Plenum Press, New York (1980)). The axons of 35 the neuroepithelia of the vomeronasal organ, located

supra palatinal, form the vomeronasal nerve and have direct synaptic connection to the accessory olfactory bulb and indirect input from there to the cortico-medial amygdaloid basal forebrain and hypothalamic nuclei of the brain. The distal axons of terminalis nerve neurons may also serve as neurochemical receptors in the VNO. Stensaas, L.J., et al., J. Steroid Biochem. and Molec. Biol. (1991) 39:553. This nerve has direct synaptic connection with the hypothalamus.

Johnson, A. et al. (J. Otolaryngol (1985) 14:71-79) report evidence for the presence of the vomeronasal organ in most adult humans, but conclude that the organ is probably non-functional. Contravening results which suggest that the VNO is a functional chemosensory receptor are reported by Stensaas, L., et al., supra; and by Moran, D.T., et al., Garcia-Velasco, J. and M. Mondragon; MontiBloch, L. and B. Grosser all in J. Steroid Biochem. and Molec. Biol. (1991) 39.

It is apparent that it would be desirable to identify and synthesize human vomeropherins and pheromones and to develop pharmaceutical compositions and methods of use to influence hypothalamic function. This invention relates to the unexpected discovery that, when nasally administered to human subjects, certain neurochemical ligands, particularly 19-nor-pregnane steroids, 19-nor-pregnene steroids and related compounds, or pharmaceutical compositions containing 19-nor-pregnanes, 19-nor-pregnenes or related compounds, specifically bind to chemoreceptors of certain nasal neuroepithelial cells and this binding generates a series of neurophysiological responses resulting in an alteration of hypothalamic function of an individual. When properly administered, the effect of certain of these compounds on the hypothalamus affects the function of the autonomic nervous system and a variety of

behavioral-or physiological phenomena which include, but are not limited to the following: anxiety, premenstrual stress, fear, aggression, hunger, blood pressure, and other behavioral and physiological functions normally regulated by the hypothalamus. See Otto Appenzeller, The Autonomic Nervous System. An Introduction of Basic and Clinical Concepts (1990); Rorner, P.I. Central nervous control of autonomic cardiovascular function, and Levy N.M. and Martin, P.J. Neural control of the heart, both in Handbook of Physiology: Section 2: Cardiovascular System - the heart, Vol. I, Washington, DC, 1979, American Physiological society; Fishman, A.P., et al. editors, Handbook of Physiology: Section 3: Respiratory System. Vol. II. Control of Breathing, Bethesda MD. 1986. American Physiological Society.

In some instances a single 19-nor-pregnane steroid, or related compound, is administered, in some instances combinations of 19-nor-pregnane steroids and/or related compounds are administered and in some instances one or more 19-nor-pregnane steroids are coadministered along with one or more estrane or estrene steroids, androstane or androstene steroids or a related compound.

Background of the Invention

Definitions

An "affect" is a transient feeling state. Typical negative affects are feelings of nervousness, tenseness, shame, anxiousness, irritability, anger, rage, and the like. "Moods" are longer lasting feeling states such as guilt, sadness, hopelessness, worthlessness, remorsefulness, misery, unhappiness and the like. "Character traits" are more permanent aspects of an individual's personality. Typical negative character traits are sensitivity, regretfulness, blameworthiness, stubbornness, resentment, bitterness, timidity,

laziness and the like.


"Pregnane steroids" are aliphatic polycyclic hydrocarbons characterized by a four-ring steroidal structure with a methylation at the 10- and 13-positions and ethylation (including unsaturated groups) at the 17-position. The 19-nor compounds lack a methyl or other carbon-containing substituent on C-10 where C-19 would normally be found. A pregnene is a subset of pregnanes commonly understood to mean that the compound has at least one double bond.

A "chemoreceptor" is a receptor molecule displayed on the surface of a "chemosensory" neuroepithelial cell which binds in a stereospecific fashion to a particular ligand or ligands. This specific binding initiates a signal transduction which initiates an afferent nerve impulse. Chemoreceptors are found, inter alia, in taste buds, olfactory epithelium and vomeronasal tissue.

"Pregnene steroids", as the term is used herein, are aliphatic polycyclic hydrocarbons with a four-ring steroidal structure, at least one double bond in the A-ring, methylation at the 10-position and 13-position, ethylation (including unsaturated groups) at the 17-position and an oxo, hydroxyl or hydroxyl derivative such as an alkoxy, ester, benzoate, cypionate, sulfate or glucuronide, at the 3-position. The 19-nor compounds lack a methyl or other carbon-container substituent or C-10 where C-19 would normally be found. Derivatives which contain these structural characteristics are also referred to generically as pregnene steroids.

The following structure shows the four-ring steroidal structure common to pregnane and pregnene steroids. In describing the location of groups and substituents, the following numbering system will be employed:


THIS SHEET HAS BEEN
REPLACED



"Sexually dimorphic" refers to a difference in the effect of, or response to, a pharmaceutical agent between males and females of the same species.

An "effective amount" of a drug is a range of quantity and/or concentration which brings about a desired physiological and/or psychological effect when administered to an individual in need of the drug. In the present case, a needy individual is one with a physiological or behavioral trait which is normally regulated by the hypothalamus and wherein it is desirable to affect the function of the hypothalamus or the trait. The effective amount of a given drug may vary depending upon the function to be affected, the desired effect, route of administration, and the like. For example, when the steroid is administered as a solution applied to the facial skin of a subject an effective concentration is from 1 microgram/ml to 100 $\mu\text{g/ml}$, preferably 10 to 50 $\mu\text{g/ml}$ and most preferably 20 to 30 $\mu\text{g/ml}$. When the steroid is introduced directly into the VNo an effective amount is about 1 picogram to about 1 nanogram, more preferably about 10 picograms to about 50 picograms. When the steroid is administered to the nasal passage, by ointment, cream or aerosol, or the like, an effective amount is about 100 pg to about 100 micrograms, preferably about 1 ng to about 10 micrograms. It follows that some drugs may be effective when administered by some routes, but not effective when administered by other routes.

The "hypothalamus" is the portion of the diencephalon comprising the ventral wall of the third



ventricle below the hypothalamic sulcus and including structures forming the ventricle floor, including the optic chiasma, tuber cinereum, infundibulum, and mammillary bodies. The hypothalamus regulates the autonomic nervous system and controls several physiological and behavioral functions such as the so-called fight and flight responses, sexual motivation, water balance, sugar and fat metabolism, hunger, regulation of body temperature, endocrine secretions, and others. The hypothalamus is also the source of vasopressin which regulates blood pressure, and oxytocin which induces parturition and milk release. All hypothalamic functions are potentially modulatable by the vomeropherin therapy described herein.

A "ligand", as used herein, is a molecule which acts as a chemical signal by specifically binding to a receptor molecule displayed on the surface of a receptor cell, thereby initiating a signal transduction across the cell surface. Binding of ligands to chemosensory receptors can be measured. Chemosensory tissue, such as vomeronasal neuroepithelium or olfactory neuroepithelium, contains a multiplicity of neuroreceptors cells, each displaying at least one cell surface receptor. Many of the receptor molecules have identical ligand specificity. Therefore, when the tissue is exposed to a ligand for which it has specificity (for example a exposure of the VNO to a vomeropherin) a summated change in cell surface receptor potential can be measured.

As used herein, "lower alkyl" means a branched or unbranched saturated hydrocarbon chain of 1 to 4 carbons, such as, for example, methyl, ethyl, n-propyl, i-butyl and the like. "Alkoxy" as used herein is used in its conventional sense to mean the group -OR wherein R is alkyl as herein defined.

A "pheromone" is a substance that provides

chemical means of communication between members of the same species through secretion and peripheral chemoreception. In mammals pheromones are usually detected by receptors in the vomeronasal organ of the nose. Commonly, pheromones effect development, reproduction and related behaviors. A "vomeropherin" is a more general term which includes pheromones and describes a substance from any source which functions as a chemosensory messenger, binds to a specific vomeronasal neuroepithelial receptor, and induces a physiological or behavioral effect. The physiologic effect of a "vomeropherin" is mediated through the vomeronasal organ.

A picogram (pg) is equal to .001 nanograms (ng). A ng is equal to .001 micrograms (μ g). A μ g is equal to .001 mg.

The invention is directed to a group of certain 19-nor pregnane steroids.

A subset of 19-norpregnanes within the group are believed to be novel. Syntheses are described herein for the following compounds as designated on the chart: Chart 1 includes 19-norpregnanes to which the invention is directed, but do not limit its scope. The synthesis diagrams that follow depict intermediate and substructure syntheses for the preparation of these 19-norpregnanes.

Brief Description of the Drawings

FIG. 1 and FIG. 2 show the EVG and vomeronasal nerve discharge frequency, respectively, of steroid E2/P4 and control, in female rats.

FIGS. 3 through 24 show the EVG, EDA, RF, CF, EMG, BT and EEG (alpha-V, alpha-T, beta-V and beta-T) data of administration of designated 19-nor-steroids in the VNO women.

FIGS. 25 through 46 show the EVG, EDA, RF, CF, EMG, BT and EEG data of administration of designated 19-

nor-steroids in the VNO of men.

Summary of the Invention

Accordingly, it is an object of this invention to provide pharmaceutical compositions which contain human vomeropherins or pheromones and are suitable for nasal administration in an individual.


It is also an object of this invention to provide methods of using these compositions to alter hypothalamic function of an individual.

10 It is a further object of this invention to provide methods of using these compositions to affect physiological and behavioral functions of individuals which are normally regulated by the hypothalamus.

Finally, it is an object of this invention to provide methods of altering hypothalamic function which have the following advantages: 1) administration directly to the chemoreceptors in the nasal passage and the vomeronasal organ, without pills or needles - i.e., non-invasively; 2) a mode of drug action through the nervous system and not through the circulatory system - thus brain function can be affected without consideration of the bloodbrain barrier; 3) a direct means of affecting the hypothalamus - there is only one synaptic junction between pheromone receptors and the hypothalamus; and, 4) providing a highly specific drug effect, thereby greatly reducing the potential for undesirable side-effects - this because sensory nerves are addressed to a specific location in the brain. Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.

Objects of this invention are achieved by

providing a pharmaceutical composition suitable for nasal administration in an individual. The composition contains a pharmaceutically acceptable carrier and a pregnane steroid with the formula:



- 5 wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionyloxy, α - or β -lower acetoxy, α - or β -lower acyloxy, or α - or β -benzyloxy;

- "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j" to form a triple bond;

P_2 is hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P_2 is absent;

- P_3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P_4 is methyl or ethyl;

P_5 is hydrogen, methyl or halo;

P_6 is hydrogen or methyl.

- One class of preferred steroid compositions contain steroids wherein "d" is a double bond, and optionally "b" is present as a double bond. Another preferred class has "a", "d" and "e" present, and g or h are optionally present. If "g" is present in this case,



then "n" is optionally present. Another preferred class has "c" present, with "f" optionally present.

The novel class of 19-nor-pregnanes are those of the above formula, excluding the following compounds in the instances where P_3 and P_6 are hydrogen; "f", "n", "h" and "g" are absent; P_4 is methyl and R' and R'' are not halo:

i) when P_1 is oxo, "c" is present and P_2 and P_5 are hydrogen; then either of "j" or "i" cannot be present alone, "m" and "j" cannot be present together, or "i" and "j" cannot be present together, or "m", "j" and "k" cannot be present together, and at least one of "i", "j" and "k" must be present;

ii) when P_1 is OH, "a", "d" and "e" are present and P_5 is hydrogen, then any of "j", "i", or "m" cannot be present alone, or "j" and "k" cannot be present together, or "i" and "j" cannot be present together, or "m", "j" and "k" cannot be present together, and at least one of "i", "j", "k" and "m" must be present;

iii) when P_1 is beta-OH, "c" is present, and P_2 and P_5 are hydrogen, then "i" and "j" cannot be present together, or "m", "j" and "k" cannot be present together;

iv) when P_1 is -OME and "d" and "b" are present, then either of "j" and "i" cannot be present alone;

v) when P_1 is oxo and "d" is present and P_5 is hydrogen; then "i" cannot be present alone or "j" and "k" cannot be present together.

The term lower alkyl, lower alkoxy, etc., is meant to encompass carbon chains of 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms.





















































Other objects of this invention are achieved by providing a method of altering hypothalamic function and/or autonomic function in an individual. A ligand for a chemoreceptor displayed on the surface of a nasal

neuroepithelial cell is provided wherein the cell is a part of tissue other than olfactory epithelia; and, the ligand is administered within a nasal passage of the individual such that the ligand binds specifically to the chemoreceptor, resulting in an alteration of hypothalamic function of the individual.

All embodiments of this application relate to and include the functional equivalents of the steroid structures disclosed in these embodiments and to those modified steroids which demonstrate said functional equivalence,

In the following chart, particularly preferred 19-nor-pregnanes are shown.





































19-NORPREGNANES

E/P	1	2	3	4	5	6	7	8
1	 KNOWN	 KNOWN	 NOVEL	 KNOWN	 KNOWN	 KNOWN	 KNOWN	 KNOWN
2	 KNOWN	 KNOWN	 KNOWN	 KNOWN	 KNOWN	 NOVEL	 KNOWN	 KNOWN
3	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 KNOWN	 KNOWN
4	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
5	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
6	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
7	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL






This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED





E P						
	1	2	3	4	5	6
8	 KNOWN	 KNOWN	 NOVEL	 NOVEL	 NOVEL	 NOVEL
9	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
10	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
11	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
12	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
13	 NOVEL	 KNOWN	 NOVEL	 NOVEL	 KNOWN	 NOVEL




SUBSTRUCTURE SYNTHESSES: TYPE E**E1:**

Frank B. Colton, Leonard N. Nysted, Byron Riegel, and Albert L. Raymond, *J. Amer. Chem. Soc.*, 1957, **79**, 1123.



Also a commercially available substructure, for example 17 α -ETHYNYL-19-NORTESTOSTERONE.

**E2:**

This is a commercially available substructure, for example ESTRONE, ETHYNYLESTRADIOL.


E3:

Pierre Crabble, U.S. Patent 3,492,318, 1970.

E4:


This is a commercially available substructure, for example 6-DEHYDROESTRONE.

E5:








See Example.

E6:




See Example.

EZ:




See Example.

E8:



O. I. Fedorova, O. S. Anisimova, and G. S. Grinenko, *Khim. Prir. Soedin* ., 1976, 2, 180.





Frank B. Colton, Lenoard N. Nysted, Byron Riegel, and Albert L. Raymond, *J. Amer. Chem. Soc.*, 1957, 79, 1123.

E9:







This is a commercially available substructure, for example EQUILIN.

E10:
















This is a commercially available substructure, for example EQUILENIN.

E11:





See Example.

E12:**See Example.****E13:****See Example.**

SUBSTRUCTURE SYNTHESSES: TYPE P**P1:**




O. I. Fedorova, O. S. Anisimova, and G. S. Grinenko, *Khim. Priir. Soedin.*, 1976, 2, 180.





Richard H. Peters, David F. Crowe, Mitchell A. Avery, Wesley K. M. Chong, and Masato Tanabe, *J. Med. Chem.*, 1989, 32, 1642.

Also See Example.


P2:




Frank B. Colton, Leonard N. Nysted, Byron Riegel, and Albert L. Raymond, *J. Amer. Chem. Soc.*, 1957, 79 1123.




Richards H. Peters, David F. Crowe, Mitchell A. Avery, Wesley K. M. Chong, and Masato Tanabe, *J. Med. Chem.*, 1989, 32, 1642.

P3:

H. Kaufmann, P. Wieland, and J. Kalvoda, *Helv. Chim. Acta.*, 1972, 55(2), 381.


P4:

O. I. Fedorova, O. S. Anisimova, and G. S. Grinenko, *Khim. Prir. Soedin.*, 1976, 2, 180.





Richard H. Peters, David F. Crowe, Mitchell A. Avery, Wesley K. M. Chong, and Masato Tanabe, *J. Med. Chem.*, 1989, 32, 1642.

P5:





Peter Kaspar and Herbert Witzel, *J. Steroid Biochem.*, 1985, Vol. 23, No. 3, p. 259.







Richard H. Peters, David R. Crowe, Mitchell A. Avery, Wesley K. M. Chong, and Masato Tanabe, *J. Med. Chem.*, 1989, 32, 1642.

P6:





Frank B. Colton, U.S. Patent 2,840,582, 1958.

P2:







Pierre Crabble and Esperanza Velarde, U.S. Patent 3,681,410, 1972.





Peter Kaspar and Herbert Witzel, *J. Steroid. Biochem.*, 1985, Vol. 23, No. 3, P. 259.

P8:

TsOH/Ac₂O
OR
POCl₃TsOH/Ac₂O

Pierre Crabble, U.S. Patent 3,492,318, 1970.


POCl₃

Klaus Prezewowsky and Rudolf Wiechert, U.S. Patent 3,682,983, 1972.


METHYLNORPREGNANES

19-Norpregnanes in this series may be prepared with a methyl group in the 6 α , 7 α , 18, 20, or 21 positions.


U.S. patent 3,681,410 teaches preparation of 6 α -methyl analogs.



U.S. Patent 3,682,983 teaches preparation of 18-methyl analogs.




U.S. Patent 3,492,318 teaches preparation of 7 α , 18, and 21-methyl analogs.



This Sheet Has Been Replaced




21-methyl analog:





L.A. Van Dijck, B.J. Lankwerden, J.G.C.M. Vermeer, and
 5 A.J.M. Weber, *Recl. Trav. Chim. Pays-Bas Belg.*, 1971, 90,
 801.

7 α , 18, 20, and 21-methyl analogs.



Richard H. Peters, David F. Crowe, Mitchell A. Averey, Wesley K. M. Chong, and Masato Tanabe, *J. Med. Chem.*, 1989, 32, 1642.


In addition certain methylated precursors are commercially available, for example:







From these, 7 α -methyl or 18-methyl analogs may be made of substances wherein estrone or 17 α -ethynyl-19-nortestosterone (norethindrone) are the precursors, respectively.

HALONORPREGNANES

U.S. Patent 2,840,582 teaches the preparation of:



U.S. Patent 3,681,410 teaches the preparation of:



Richard H. Peters, David F. Crowe, Mitchell A. Avery, Wesley K. M. Chong, and Masato Tanabe, *J. Med. Chem.*, 1989, 32, 1642.

Alkoxy derivatives are prepared from their corresponding hydroxy steroids by reaction with an alkylating agent such as trimethyloxonium fluoroborate, triethyloxonium fluoroborate or methylfluorosulfonate in an inert chlorocarbon solvent such as methylene chloride. Alternatively, alkylating agents such as alkyl halides, alkyl tosylates, alkyl mesylates and dialkylsulfate may be used with a base such as NaH, KM or KOBut, silver oxide or barium oxide in polar, aprotic solvents as for example, DMF, DMSO and hexamethylphosphoramide.

General procedures for synthetic reactions of steroids are known to those skilled in art. Where time and temperature of reactions must be determined, these can be determined by a routine methodology. After addition of the required reagents, the mixture is stirred under an inert atmosphere and aliquots are removed at hourly intervals. The aliquots are analyzed by chromatography to monitor the disappearance of starting material, at which point the work-up procedure is initiated. If the starting material is not consumed within twenty-four hours, the mixture is heated to reflux and hourly aliquots are analyzed, as before, until the starting material disappears. In this case the mixture is allowed to cool before the work-up procedure is initiated.

Purification of the products is accomplished by means of chromatography and/or crystallization, as known to those skilled in the art.

Pharmaceutical Compositions and Methods of Use

An embodiment of the subject invention is a method of altering the hypothalamic function of an individual. Another embodiment is altering an autonomic function of an individual. These autonomic functions include but are not limited to heart rate, respiratory rate, brain wave

patterns (percentage alpha cortical activity), body temperature. Other embodiments include, but are not limited to, methods of diminishing negative affect, negative mood or negative character traits of an individual. Another embodiment is a method of treating female premenstrual stress. All of these embodiments are accomplished by means of the non-systemic, nasal administration of certain pregnane steroids, combinations of pregnane steroids and combinations of one or more pregnane steroids and one or more androstane and/or estrene steroids.

This particular mode of administration is distinguished from alternative modes, such as ingestion or injection, in several important ways, these by virtue of the direct contact with the VNO provided by the nasal administration of the steroid ligand. In the methods of this invention, the appropriate ligand is administered directly to the chemoreceptors in the nasal passage and the vomeronasal organ, without pills or needles - i.e., non-invasively. Drug action is mediated through binding of the ligands, described herein, to specific receptors displayed by neuroepithelial cells in the nose, preferably in the VNO. This furthermore, the mode of drug action is through the nervous system and not through the circulatory system - thus brain function can be affected without consideration of the blood-brain barrier. These methods of treatment provide a direct means of affecting the hypothalamus through the nervous system because there is only one synaptic junction between pheromone receptors and the hypothalamus. Because sensory nerves are addressed to a specific location in the brain, this method has a highly specific drug effect, thereby greatly reducing the potential of undesirable side-effects.

VNO contact is important because the VNO is

associated with chemoreceptive/pheromonal function. The VNO consists of a pair of blind tubular diverticula which are found at the inferior margin of the nasal septum. The VNO contains neuro-epithelia, the axons of which have
5 direct synapses to the amygdala and from there, to the hypothalamus. The existence of the VNO has been well documented in most terrestrial vertebrates including the human fetus; however, in adult humans it is generally thought to be rudimentary (See Johnson, et al., supra).

10 Antifertility Activity

The steroid 19-norpregna-1,3,5(10)-trien-3-ol (compound E2/P4 in the 19-norpregnane chart) was tested in the VNO of female rats. The EVG and vomeronasal nerve (VNn) discharge frequency are shown in Figures 1 and 2,
15 respectively. This data shows stimulation of the VNO. The steroid E2/P4 was shown to have postcoital antifertility activity when administered orally to female rats while having low hormonal activity (measured by estrogen-receptor binding). (Peters, et al., J. Med.
20 Chem., 1989, 32,1642-52.) The data in Figures 1 and 2 suggest that this antifertility activity is explainable because E2/P4 is not a hormone, but acts as a vomeropherin through stimulation of the VNO, which in turn affects the hypothalamus. Consistent with the rat
25 model data, the compound E2/P4 also shows VNO stimulation in women (see Figure 22), and to a lesser extent, in men (see Figure 44), and thus it is expected that the vomeropherins have antifertility activity in humans.

Stimulation of the hypothalamus via the VNO may
30 allow one to suppress release of LH and FSH. This can provide a clinical method for treatment of prostatic cancer, precocious puberty (in males and females), endometriosis, uterine leiomyoma, breast cancer,

premenstrual syndrome and dysfunctional uterine bleeding.

The ligand substances described herein, or their sulfated cypionated, benzoated, proprionated, or glucuronated derivatives, may be administered directly, but are preferably administered as compositions. They are prepared in a liquid dosage form such as, for example, liquids, suspensions or the like, preferably in unit dosage forms suitable for single administration of precise dosages. Liquid dosages may be administered as nose drops or as an aerosol. Alternatively, the active compound can be prepared as a creme or an ointment composition and applied topically within the nasal cavity. In addition, a vomeropherin may be administered as vapor contained in an air puff delivered in the nasal cavity. As another alternative, delivery may occur by controlled release of these agents by encapsulation either in bulk or at a microscopic level using synthetic polymers, such as silicone, and natural polymers such as gelatin and cellulose. The release rate can be controlled by proper choice of the polymeric system used to control the diffusion rate (Langer, R.S. and Peppas, N.A., Biomaterials 2,201, 1981). Natural polymers, such as gelatin and cellulose slowly dissolve in a matter of minutes to hours while silicone remains intact for a period of months. The compositions will include a conventional pharmaceutical carrier or excipient, one or more of the active 19-nor-pregnane compound(s), and the composition may or may not additionally include one or more androstane or estrene steroids. In addition, the compositions may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

The most likely means of communication of a semiochemical ligand is the inhalation of a naturally occurring pheromone present on the skin of another. It is estimated that the naturally occurring maximum

concentration of a pregnane steroid on human skin is from 2 to 7 ng/cm². During intimate contact it is estimated that a human would be exposed to no more than 700 ng of a naturally occurring steroid. Since these compounds are
5 relatively nonvolatile, it is estimated that, even during intimate contact, a human subject would inhale no more than 0.7 pg of a naturally occurring steroid from the skin of another. From the a count inhaled only about 1% would reach the receptors of the vomeronasal organ. Thus
10 the estimated maximum natural exposure to naturally produced pheromones would be 0.007 pg.

The amount of vomeropherin administered will of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration,
15 the frequency of administration, and the judgment of the prescribing physician. However, a single dosage of at least about 10 picograms, delivered directly into the lumen of the vomeronasal organ, is effective in eliciting a transient autonomic response. When administered to the
20 nasal cavity, the dosage is about 100 picograms to about 10 micrograms, preferably about 1 nanogram to about 10 micrograms, more preferably about 10 nanograms to 1 about microgram. The frequency of administration is desirably in the range of an hourly dose to a monthly dose,
25 preferably from 8 times/day to once every other day, more preferably 1 to 3 times per day. Ointments containing one or more active compounds and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the
30 like, can be prepared using a base such as, for example, petroleum jelly, lard, or lanolin.

Liquified pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and
35 optional pharmaceutical adjuvants in a carrier, such as,

for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of
5 nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are
10 known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 15th Ed., 1975. The composition or formulation to be administered will, in any event, contain a quantity of one or more of the
15 active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

For aerosol administration, the active ingredient is preferably supplied in finely divided form along with a surfactant and a propellant. Typical percentages of
20 active ingredients are 0.001 to 2% by weight, preferably 0.004 to 0.10%.

Surfactants must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty
25 acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, oleostearic and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol,
30 mannitol, sorbitol, and hexitol anhydrides derived from sorbitol (the sorbitan esters sold under the trademark "Spans") and the polyoxyethylene and polyoxypropylene derivatives of these esters. Mixed esters, such as mixed or natural glycerides, may be employed. The preferred
35 surface-active agents are the oleates or sorbitan, e.g.,

those sold under the trademarks "Arlacel C" (sorbitan sesquioleate), "Span 80" (sorbitan monooleate) and "Span 85" (sorbitan trioleate). The surfactant may constitute 0.1-20% by weight of the composition, preferably 0.25-5%.

5 The balance of the composition is ordinarily propellant. Liquified propellants are typically gases at ambient conditions, and are condensed under pressure. Among suitable liquefied propellants are the lower alkanes containing up to five carbons, such as butane and
10 propane; fluorinated or fluorochlorinated alkanes, such as are sold under the trademark "Freon". Mixtures of the above may also be employed.

 In producing the aerosol, a container equipped with a suitable valve is filled with the appropriate
15 propellant, containing the finely divided active ingredient and surfactant. The ingredients are thus maintained at an elevated pressure until released by action of the valve.

 Yet another means of administration is topical
20 application of a volatile liquid composition to the skin, preferably facial skin, of an individual. The composition will usually contain an alcohol such as ethanol or isopropanol. A pleasant odorant may also be included in the composition.

25 Measuring Affect, Mood and Character Trait

 Feeling states associated with affects, moods and character traits are generally measured by use of a questionnaire. For example questionnaires comprising a number of adjectives which refer to feeling states may be
30 administered to an individual. The individual evaluates his or her feeling state described by the adjective and rates the intensity of the feeling on a numerical scale. Clustering of related adjectives and statistical analysis of a subject's evaluation of each adjective provides a

basis for the measurement of various feeling states.



Alternatively, feeling states may be measured by autonomic changes, such as those used in polygraphic evaluations (galvanic skin response, pulse rate and the like). Cabanac, M. Annual Review of Physiology (1975) 37:415; Hardy, J.D., "Body Temperature Regulation", Chapter 59, pp. 1417. In: Medical Physiology. Vol. II Ed.: VB Mountcastle (1980); Wolfram Bouscein. Electrodermal Activity (Plenum Press 1992). In addition, non-verbal cues such as facial expression and body posture may be evaluated.

Examples



The following examples are intended to illustrate but not to limit the invention.

Abbreviations used in the examples are as follows:
aq.= aqueous; RT.=room temperature; PE=petroleum ether (b.p. 50-70°); DMF=N,N-dimethylformamide; DMSO=dimethyl sulfoxide; THF=tetrahydrofuran.


Scheme 1. Syntheses of 19-norpregnanes.




This Sheet Has Been Replaced

THIS SHEET HAS BEEN
REPLACED

Scheme 2. Syntheses of further norpregnanes.







THIS SHEET HAS BEEN
REPLACED



This Sheet Has Been Replaced






Scheme 3. Further syntheses of norpregnanes.

THIS SHEET HAS BEEN
REPLACED

This Sheet Has Been Replaced



Scheme 4. 17-Ethylenation of ketones.



THIS SHEET HAS BEEN
REPLACED

This Sheet Has Been Replaced



Example 1

19-Norpregna-4,20-dien-3 β -ol, 1: A suspension of 19-norpregna-4,20-dien-3-one (0.38 g, 13 mmol) and lithium
5 tri-*t*-butoxyaluminumhydride (1.36 g, 5.35 mmol) in 20 mL of anhydrous ether was stirred 5 h at room temperature, following which Glauber's salt (6.74 g) was added. The resulting mixture was stirred 5 min. and then filtered through a glass frit. The residue was washed with 5 20 mL portions of ether and the combined filtrates were concentrated under reduced pressure. The crude product was purified by preparative TLC on silica gel GF using 5% ethyl acetate/methylene chloride as eluent to give a yellow resin (39.6 mg, 0.138 mmol, 11%) homogeneous to
10 TLC (5% ethyl acetate/methylene chloride on silica gel; R_f 0.29).

Example 2

19-Norpregna-1,3,5(10),17,20-pentaen-3-ol, 2: To a suspension of lithium aluminum hydride (LAH, 256.1 mg, 6.748 mmol) and aluminum chloride (296.8 mg, 2.227 mmol) in 20 mL of anhydrous ether under argon was added
20 ethinylestradiol (1.0000 g, 3.3738 mmol) in 20 mL anhydrous ether. After refluxing 20 h the reaction was quenched with the addition of Glauber's salt (2.00 g) and stirring a further 2 h. The mixture was then filtered through
25 diatomaceous earth and the residue was washed with 3 10 mL portions of ethyl acetate. Concentration of the combined filtrates, flash chromatography on silica gel with 15% ethyl acetate/hexanes, and twofold
30 recrystallization from aqueous ethanol gave slightly tan needles (367.5 mg, 1.311 mmol, 39%), m.p. 132-133°C, homogeneous to TLC (20% ethyl acetate/hexanes on silica gel; R_f 0.36; estro-1,3,5(10),16-tetraen-3-ol R_f 0.36).

Example 3

19-Norpregna-1,3,5(1)-trien-3-ol-20 β -yne, 3: To a cooled (dry ice/acetone bath) solution of 19-norpregna-1,3,5(10),17,20-pentaen-3-ol (2, 280.4 mg, 1.000 mmol) in 28 mL of anh. THF under argon was added n-BuLi (2.5 M in hexane, 1.2 mL, 3.0 mmol) over 10 min. Stirring was continued for 18 h, during which the reaction was allowed to gradually warm to RT. The reaction was quenched with 25 mL of 1 N HCl and then extracted with 3 10 portions of ether. The combined organic extracts were washed with 25 mL of saturated sodium bicarbonate +25 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography of the resulting yellow resin on silica gel with 20% ethyl acetate/hexanes, followed by recrystallization from aqueous ethanol gave fine, white needles (150.5 mg, 0.5367 mmol, 54%), m.p. 148-149°C, homogeneous to TLC (20% ethyl acetate/hexanes on silica gel; R_f 0.34; starting material R_f 0.37).

Example 4

19-Norpregna-1,3,5(10),16,20-pentaen-3-ol, 4: 19-Norpregna-1,3,5(10),16-tetraen-3-ol-20-yne (200.0 mg, 0.7184 mmol) in 9 mL anh. THF was added to approx. 30 mL of anh. ammonia. Sodium (0.07 g, 3 mg-atom) was added in small pieces and the reaction was stirred 1 h, during which the color disappeared. Abs. ethanol (3 mL) was added and the mixture was allowed to warm to RT overnight. HCl (1 N, 20 mL) was added the mixture was extracted three times with 10 mL portions of methylene chloride. The combined organic extracts were washed with 10 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of methylene chloride and the combined

filtrates were concentrated under reduced pressure. Preparative TLC (silica gel GF, with 20% ethyl acetate/hexanes) of the resulting amber resin, followed by recrystallization from benzene/hexanes gave an off-white powder, m.p. 123-125°C. TLC (20% ethyl acetate/hexanes) showed a major product (R_f 0.38) with a minor contaminant (R_f 0.04).

Example 5

10 19-Norpregna-5(10),20-dien-3-one, 5: 19-Norpregna-2,5(10),20-trien-3-yl methyl ether (750.0 mg, 2.513 mmol) was dissolved in 80 mL of acetone and oxalic acid (0.88 g, 7.0 mmol) in 12 mL of water was added. Further acetone (20 mL) was added to bring most of the precipitate back into solution and the reaction was stirred 6 h. Following saturated sodium bicarbonate quench (30 mL) the reaction mixture was twice with 40 mL portions of ethyl acetate. The combined organic extracts were washed twice with 50 mL portions of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 25 mL of ethyl acetate and the combined filtrates were concentrated under reduced pressure. Flash chromatography (10% ethyl acetate/hexanes on silica gel) gave a colorless resin (0.54 g, 1.9 mmol, 76%).

Example 6

30 19-Norpregna-5(10),20-dien-3-ol, 6: To an ethereal (8.4 mL) solution of 19-norpregna-5(10),20-dien-3-one (0.42 g, 1.5 mmol) was added 69.7 mg (1.84 mmol) of LAH and the reaction was stirred 30 min. Glauber's salt (2.79 g) was added and the suspension was stirred an additional 10 mL. The mixture was then filtered through diatomaceous earth and the residue was extracted with 435

mL portions of ether. The combined filtrates were concentrated under reduced pressure and the resulting oil was flash chromatographed (20% ethyl acetate/hexanes on silica gel) to give an off-white foam (0.38 g, 1.3 mmol, 88%).

Example 7

19-Norpregna-4,20-dien-10 β -ol-3-one, 7: 19-Norpregna-5(10),20-dien-3-one (5.045 g, 1.6 mmol) in DMF (5.7 mL) was cooled in an ice-acetone bath and Jones reagent (2.67 M, 0.19 mL, 0.51 mmol) was added. After stirring 1 1/2 h a further 0.19 mL of Jones reagent were added. Stirring was continued 45 min., after which 0.38 mL of Jones reagent were added. The reaction was quenched after stirring 1 more hour by the addition of 2-propanol (0.38 mL). Ethyl acetate (100 mL) was added and the mixture was washed with 3 50 mL portions of water + 50 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ethyl acetate and the combined filtrates were concentrated under reduced pressure. Preparative TLC on alumina with 50% ethyl acetate/hexanes gave a white, crystalline film (89.2 mg, 0.297 mmol, 19%). TLC (50% ethyl acetate/hexanes on silica gel) showed mostly produce (R_f 0.46), contaminated with a little starting material (R_f 0.73).

Example 8

19-Norpregna-4,9(10),20-trien-3-one, 8: A solution of 19-Norpregna-5(10),20-dien-3-one (0.34 g, 1.2 mmol) in anh. Pyridine (4.0 mL, 49 mmol) was cooled in an ice-salt bath to below -8°C and solid pyridinium bromide perbromide (1.26 g, 3.94 mmol) was added at such a rate that the reaction temperature did not exceed -2°C.

After stirring 1 min., 0.20 g of phenol were added, the cold bath was removed, and the reaction was stirred at RT for 24 h. Ethyl acetate (50 mL) was added and the mixture was washed with 50 mL of 1 N HCl + 25 mL of saturated CuSO₄ + 25 mL of 5% sodium hydroxide + 25 mL of water + 25 mL of brine. The mixture was then dried over sodium sulfate for 4 h and afterwards filtered through a glass frit. The residue was washed with 10 mL of ethyl acetate and the combined filtrates were concentrated under reduced pressure. The resulting dark syrup (512.8 mg) was taken up in 8 mL of abs. ethanol, zinc dust (260.8 mg, 3.990 mg-atom) was added, and the suspension was refluxed 1/2 h. The reduction mixture was filtered through cotton and the residue was washed with 10 mL of ethanol. Concentration of the combined filtrates and two-fold purification by preparative TLC, first on silica gel GF (1000 μ , 20% ethyl acetate/hexanes as eluent) then on alumina GF (1000 μ , 20% ethyl acetate/hexanes), gave a nearly colorless resin (152.8 mg, 0.5410 mmol, 45%) homogeneous to TLC (R_f 0.22, 10% ethyl acetate/hexanes on silica gel; *pregna-4,20-dien-3-one* R_f 0.25).

Example 9

19-Norpregna-1,3,5(10),20-tetraen-3-ol, 9:

Ethynylestradiol diacetate (2.0004 g, 5.2576 mmol) in 100 mL of anh. THF was added to approx. 140 mL of anh. NH₃ and sodium (1.88 g, 81.8 mg-atom) was added in small slivers over 5 min. After stirring the dark blue solution 1 h, abs. ethanol was added and the reaction was allowed to gradually warm to RT overnight. 100 mL of 1 N HCl were added, the layers were separated, and the aqueous layer was extracted twice with 50 mL portions of ether. The combined organic phases were washed with 3 100 mL portions of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was

washed with 25 mL of ether and the combined filtrates were concentrated under reduced pressure. The residue was taken up in 25 mL of methylene chloride, dried over sodium sulfate, and filtered through diatomaceous earth.

5 The residue was washed twice with 10 mL portions of methylene chloride and the combined filtrates were concentrated under reduced pressure. Flash chromatography (15% ethyl acetate/hexanes on silica gel) gave a white, crystalline solid with yellow spots (0.86

10 g, 3.0 mmol, 58%).

Example 10

19-Norpregna-1,3,5(10),20-tetraen-3-yl methyl ether, 10: To crude 19-Norpregna-1,3,5(10),20-tetraen-3-ol

15 (9, 0.86 g, 3.0 mmol) in 75 mL of 90% ethanol was added potassium carbonate (6.73 g, 55.2 mmol) and the suspension was refluxed 1/2 h. Dimethyl sulfate (0.75 mL) was added and the reaction was refluxed a further 1/2 h. Dimethyl sulfate was added in 3 1.8 mL aliquots

20 (total = 6.15 mL, 65.0 mmol) over 1 h, and reflux was continued for 1/2 h. Ice water (65 mL) was added and the mixture was cooled in an ice bath and stirred for 2 h. The suspension was centrifuged and then filtered through a coarse frit. The residue was washed with 50 mL of

25 water + 50 mL of 5% sodium hydroxide + 3 50 mL portions of water. The residue was recrystallized from aqueous ethanol to give fine white needles, m.p. 108.5-110°C (lit.m.p. 108-110°C).

Example 11

30 19-Norpregna-1,3,5(10),16-tetraen-6-on-20-yn-3-yl acetate, 11: Chromium trioxide (2.68 g, 2.68 mmol) was suspended in 40 mL of methylene chloride and the suspension was cooled in an ice-salt bath to -8°C. 3,5-

Dimethylpyrazole (2.58 g, 26.8 mmol) was added and the suspension was stirred 20 min. 19-Norpregna-1,3,5(10),16-tetraen-20-yn-3-yl acetate (0.86 g, 2.7 mmol) was added over 5 min., so that the reaction temperature did not exceed -7°C. After stirring an additional 2 h, the reaction mixture was poured through a 30 mm x 116 mm column of silica gel and elution was continued under pressure with methylene chloride. Concentration of appropriate fractions gave a brown film (0.16 g, 0.48 mmol, 18%).

Example 12

19-Norpregna-1,3,5(10),16-tetraene-3,6 β -diol-20-yne, 12: Crude 19-norpregna-1,3,5(10),16-tetraen-6-on-20-yn-3-yl acetate (11, 0.16 g, 0.48 mmol) was suspended in 20 anhyd. ether, LAH (36.7 mg, 0.967 mmol) was added, and the mixture was refluxed with exclusion of water for 18 h. After cooling, 1.22 g of Glauber's salt were added and the suspension was stirred 1/2 h. The mixture was filtered through diatomaceous earth and the residue was washed with 4 10 mL portions of hot ethyl acetate. Concentration of the combined filtrates, followed by purification by preparative TLC (50% ethyl acetate/hexanes on silica gel GF, 1000 μ) gave a white solid (26.0 mg, 88.3 μ mol, 18%) homogeneous to TLC (50% ethyl acetate/hexanes on silica gel; R_f 0.48).

Example 13

19-Norpregna-1,3,5(10),17-tetraen-3-ol, 13: Ethyltriphenylphosphonium bromide (1.3947 g, 3.7572 mmol) and potassium t-butoxide (422.5 mg, 3.765 mmol) suspended in anhyd. DMSO (4.1 mL) under argon were placed in an oil bath (80-84°C) and stirred 1 h. Equilin (200.2 mg, 0.7459 mmol) in 4.1 mL of anhyd. DMSO was added and the reaction was stirred a further hour. After cooling, 25

mL of ice-1 N HCl was added and the mixture was extracted three times with 20 mL portions of ether. The combined organic extracts were washed with 25 mL of saturated sodium bicarbonate + 25 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography (20% ethyl acetate/hexanes on silica gel) followed by preparative TLC (20% ethyl acetate/hexanes on silica gel GF, 1000 μ) gave a slightly yellow resin (182.9 mg, 0.6523 mmol, 87%) homogeneous to TLC (20% ethyl acetate/hexanes R_f 0.42).

Example 14


19-Norpregna-1,3,5(10),617-pentaen-3-ol, 14:

Ethyltriphenylphosphonium bromide (1.3945 g, 3.7561 mmol) and potassium *t*-butoxide (422.8 mg, 3.768 mmol) suspended in 4.5 mL of anh. DMSO under argon were placed in a 77-79°C bath and were stirred 1 h. 6-Dehydroestrone (200.4 mg, 0.7466 mmol) in 4.1 mL of anh. DMSO was added and the reaction was stirred in 1 h. The reaction mixture was allowed to cool and was then poured into 25 mL of ice-1 N HCl. The mixture was extracted three times with 20 mL of ether and the combined organic extracts were washed with 25 mL of saturated sodium bicarbonate + 25 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography (15% ethyl acetate/hexanes) and preparative TLC (15% ethyl acetate/hexanes on silica gel GF, 1000 μ) gave an off-white crystalline solid (212.9 mg, >100%) homogeneous to TLC (15% ethyl acetate/hexanes on silica gel, R_f 0.21).

Example 1519-Norpregna-1,3,5(10),6,8,17-hexaen-3-ol, 15:

Ethyltriphenylphosphonium bromide (1.3945 g, 3.7561 mmol) and potassium *t*-butoxide (422.3 mg, 3.763 mmol) suspended
5 in 4.1 mL of anhydrous DMSO under argon were placed in an oil bath (74-83°C) and the reaction was stirred 1 h. Equilenin (200.2 mg, 0.7518 mmol) in 4.1 mL of anhydrous DMSO was added and the reaction mixture was stirred a further hour. The mixture was poured into 25 mL of ice-1 *N* HCl
10 and extracted three times with 20 mL portions of ether. The combined organic extracts were washed with 25 mL of saturated sodium bicarbonate + 25 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ether and
15 the combined filtrates were concentrated under reduced pressure. Flash chromatography (20% ethyl acetate/hexanes) and preparative TLC (20% ethyl acetate/hexanes on silica gel GF, 1000 μ) gave a light yellow, crystalline wax (180.6 mg, 0.6487 mmol, 86%)
20 homogeneous to TLC.

Scheme 5. Pd(II)-catalyzed synthesis of 19-norpregnenes.



Example 16

17-Iodo-estra-1,3,5(10),7,16-pentaen-3-ol, 16: To crude equilin 17-hydrazone (1.0058 g, $\approx$ 3.5000 mmol) in 21 mL of anh. THF + 4.4 mL (32 mmol) of triethylamine
5 under Ar atmosphere and cooled in an ice bath was added iodine (2.10 g, 16.5 mmol) in 21 mL of anh. THF over 33 min., until the yellow color persisted and gas evolution ceased (remaining I₂ solution: 5 1/2 mL). Stirring was continued 20 min., after which the reaction mixture was
10 then concentrated under reduced pressure and resuspended in 90 mL of ether. The suspension was washed with 35 mL of 1 N HCl + 35 g of 5% (w/w) sodium thiosulfate pentahydrate + 35 mL of saturated sodium bicarbonate + 35 mL of brine, dried over magnesium sulfate, and filtered
15 through diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography (20% ethyl acetate/hexanes on silica gel) of the residue yielded a yellow foam (953.8 mg, 2.522
20 mmol, 72%).

Example 17

19-Norpregna-1,3,5(10),7,16-pentaen-3-ol, 17: A mixture of 17-iodoestra-1,3,5(10),7,16-pentaen-3-ol (953.8 mg, 2.522 mmol), [1, 1'-
25 bis(diphenylphosphino)ferrocene]palladium(II)chloride CH₂Cl₂ (51.5 mg, 63.1 μ mol), 10 mL of THF, 2.8 mL (2.8 mmol) of 1.0 M triethylborane in THF, and 2.5 mL of 15% (w/w) sodium hydroxide was refluxed under Ar atmosphere for 24 h. After cooling, 10 mL of 1 N HCl were added and
30 the reaction mixture was extracted 3 times with 10 mL portions of methylene chloride. The combined organic extracts were washed with 10 mL of saturated sodium bicarbonate + 10 mL of brine, dried over magnesium

sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of methylene chloride and the combine filtrates were concentrated under reduced pressure. Preparative TLC (20% ethyl acetate/hexanes on silica gel GF, 1000 μ) of the residue yielded an amber resin (54.4 mg, 0.194 mmol, 7.7%) homogeneous to TLC (20% ethyl acetate/hexanes on silica gel; product R_f 0.39; 17-iodoestra- 1,3,5(10),16-tetraen-3-ol R_f 0.37).

Example 18

10 19-Norpregna-2,5(10),16-trien-3-yl methyl ether.
18: 19-Norpregna-1,3,5(10),16-tetraen-3-yl methyl ether (1.00 g, 2.27 mmol) in 15 mL of anh. THF + 11.14 g of t-butanol was added to ca. 100 mL of anh. ammonia, followed by 0.41 g of lithium wire cut in small pieces.
15 After stirring 4 h, the reaction was quenched with the addition of 3.8 mL of anh. methanol and ammonia was allowed to boil off for 3 h. 100 mL of water were added and the mixture was extracted twice with 100 mL portions of ether. The combined organic extracts were washed 3
20 times with 50 mL portions of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 25 mL of ether and the combined filtrates were concentrated under reduced pressure. Recrystallization of the resulting syrup from 95% ethanol
25 gave white crystals (586.7 mg, 1.966 mmol, 58%), m.p. 70-72°C.

Example 19

30 19-Norpregna-4,16-dien-3-one, 19: To a solution of 19-norpregna-2,5(10),16-trien-3-yl methyl ether (3, 298.5 mg, 1.000 mmol) in 8 mL of acetone + 2.5 mL of methanol were added 2.5 mL of 1 N HCl. After stirring 1 h, hydrolysis was stopped by the careful addition of 3.00 g of sodium bicarbonate. Once effervescence had ceased the

mixture was extracted three times with 10 mL portions of methylene chloride. The combined organic extracts were washed with 10 mL of brine, dried over sodium sulfate, and filtered through diatomaceous earth. The residue was
5 washed with 10 mL of methylene chloride and the combined filtrates were concentrated under reduced pressure. Preparative TLC (15% ethyl acetate/hexanes on silica gel GF, 1000 μ) twice of the resulting amber resin provided a yellow solid (107.4 mg, 0.3776 mmol, 38%) homogeneous to
10 TLC (15% ethyl acetate/hexanes on silica gel; product R_f 0.29; pregna-4,16-dien-3-one R_f 0.32).

Example 20

19-Norpregna-5(10),16-dien-3-one, 20: To a solution of 19-norpregna-2,5(10),16-trien-3-yl methyl
15 ether (18, 1.38 g, 4.62 mmol) in 65 mL of acetone were added 1.60 g (12.7 mmol) of oxalic acid dihydrate in 23 mL of water. 85 mL of acetone were added and the reaction mixture was stirred 8 h. Hydrolysis was stopped with the addition of 65 mL of saturated sodium
20 bicarbonate and the mixture was extracted three times with 100 mL portions of ether. The combined organic extracts were washed twice with 100 mL portions of brine, dried over sodium sulfate overnight, and filtered through a glass frit. Flash chromatography (10% ethyl
25 acetate/hexanes on silica gel) of the resulting syrup, followed by recrystallization from hexanes gave two crops of white crystals (775.8 mg, 2.727 mmol, 59%). For first crop: m.p. 82.5-85°C; TLC (5% ethyl acetate/hexanes on silica gel) R_f 0.13; 19-norpregna-4,16-dien-3-one R_f 0.03.


30

Example 21

19-Norpregna-4,16-dien-10 β -ol-3-one, 21: To a solution of 19-norpregna-5(10),16-dien-3-one (20, 341.3 mg, 1.200 mmol) in 8.2 mL of chloroform cooled in an


acetone/dry ice bath was added 3-chloroperbenzoic acid (0.89 g, 5.2 mmol) in 9 mL of ether over 5.5 min. The reaction mixture was stirred 2 h and then left in the refrigerator for 16 h. The reaction was then poured into 5 70 g of 5% (w/w) sodium thiosulfate pentahydrate and the layers were separated. The aqueous layer was extracted 3 times with 15 mL portions of ethyl acetate. The combined organic phases were washed with 15 mL of saturated sodium bicarbonate + 15 mL of brine, dried over magnesium 10 sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ethyl acetate and the combined filtrates were concentrated under reduced pressure. To the resulting white solid was added 5% (w/w) potassium hydroxide in methanol and the mixture was 15 refluxed with exclusion of moisture for 1 h. The mixture was then poured into 140 mL of ice/brine and extracted 3 times with ether. The combined organic extracts were washed twice with 100 mL portions of brine, dried over magnesium sulfate, and filtered through diatomaceous 20 earth. The residue was washed with 25 mL of ether and the combined filtrates were concentrated under reduced pressure. Preparative TLC (silica gel GF, 1000 μ), once with 50% ethyl acetate/hexanes and once with 10% ethyl acetate/methylene chloride, gave a yellow resin (157.7 25 mg, 0.5249 mmol, 44%) homogeneous to TLC (50% ethyl acetate/hexanes on silica gel; product R_f 0.32; pregnenolone R_f 0.40).

Scheme 6. Synthesis of 19-norpregnanes.



THIS SHEET HAS BEEN
REPLACED

This Sheet Has Been Replaced



Example 2219-Norpregna-2,5(10)-dien-3-yl methyl ether, 22:

A solution of 19-norpregna-1,3,5(10)-trien-3-yl methyl ether (800.0 mg, 2.680 mmol) in 12 mL of anh. THF + 8.86 g of t-butanol was added to ca. 90 mL of anh. ammonia, followed by 0.33 g of lithium wire cut in small pieces. After stirring 4 h, 3.0 mL of methanol were added and ammonia was allowed to boil off overnight. 80 mL of water were added and the mixture was extracted twice with 80 mL aliquots of ether. The combined organic extracts were washed 3 times with 40 mL portions of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 25 mL of ether and the combined filtrates were concentrated under reduced pressure. Recrystallization from aqueous ethanol delivered a white solid (638.6 mg, 2.125 mmol, 79%), m.p. 84-88°C. TLC (5% ethyl acetate/hexanes on silica gel) showed product (R_f 0.56; starting material R_f 0.49) with a trace of less polar contaminant (R_f 0.80).

20

Example 23

19-Norpregna-5(10)-en-3-one, 23: To a solution of 19-norpregna-2,5(10)-dien-3-yl methyl ether (22, 500.0 mg, 1.664 mmol) in 55 mL of acetone was added oxalic acid dihydrate (0.58 g, 4.6 mmol) in 8.3 mL of water. After stirring 7 h, 25 mL of saturated sodium bicarbonate were added and the mixture was extracted 3 times with 35 mL portions of ether. The combined organic extracts were washed 3 times with 35 mL portions of brine, dried over sodium sulfate overnight, and filtered through a coarse frit. The residue was washed with 25 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography (10% ethyl acetate/hexanes on silica gel) gave a slightly yellow syrup (394.1 mg, 1.376 mmol, 83%).

Example 24

19-Norpregn-4-en-10 β -ol-3-one, 24: To a solution of 19-norpregn-5(10)-en-3-one (23, 330.3 mg, 1.153 mmol) in 7.9 mL of chloroform cooled in an acetone/dry ice bath was added 3-chloroperbenzoic acid (0.86 g, 5.0 mmol) in 8.6 mL of ether over 6 min. After stirring 2 h, the reaction was stored in the refrigerator for 24 h. The mixture was then poured into 70 g of 5% (w/w) sodium thiosulfate pentahydrate and the layers were separated.

10 The aqueous layer was extracted 3 times with 15 mL portions of ethyl acetate. The combined organic phases were washed with 15 mL of saturated sodium bicarbonate + 15 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was


15 washed with 10 mL of ethyl acetate and the combined filtrates were concentrated under reduced pressure. To the resulting colorless syrup were added 55 mL of 5% (w/w) potassium hydroxide in methanol and the mixture was refluxed 1 h with exclusion of moisture. After cooling,

20 the reaction mixture was poured into 140 mL of brine and extracted 3 times with 100 mL portions of ether. The combined organic extracts were washed twice with 100 mL portions of brine, dried over sodium sulfate overnight, and filtered through a coarse frit. The residue was

25 washed with 25 mL of ether and the combined filtrates were concentrated under reduced pressure. Preparative TLC (10% ethyl acetate/methylene chloride on silica gel GF, 1000 μ) gave a yellow resin (105.6 mg, 0.3491 mmol, 30%). TLC (50% ethyl acetate/hexanes on silica gel)

30 showed product (R_f 0.47; pregnenolone R_f 0.42) with a trace contaminant (R_f 0.39).

Scheme 7. Additional syntheses of 19-norpregnenes.



Example 25

19-Norpregna-1,3,5(10),7,17,20-hexaen-3-yl methyl ether, 25: To lithium aluminum hydride (98.4 mg, 2.59 mmol) and aluminum chloride (115.2 mg, 0.8642 mmol) under Ar were carefully added 8.0 mL of anh. THF, followed by a solution of 19-norpregna-1,3,5(10),7-tetraen-17 β -ol-20-yn-3-yl methyl ether (400.0 mg, 1.297 mmol) in 8.0 mL of anh. THF. The reaction mixture was refluxed 24 h and then quenched with the addition of 0.77 g of Glauber's salt. After stirring a further 2 h, the mixture was filtered through diatomaceous earth and the residue was extracted three times with 5 mL portions of ethyl acetate. Concentration of the combined filtrates produced a light yellow resin, which was purified by flash chromatography (5% ethyl acetate/hexanes on silica gel), preparative TLC (5% ethyl acetate/hexanes on silica gel GF, 1000 μ), and crystallization from 95% ethanol to give very fine, white needles (140.1 mg, 0.4791 mmol, 37%), m.p. 79-96°C, homogeneous to TLC (10% ethyl acetate/hexanes on silica gel; product R_f 0.59; estra-1,3,5(10),16-tetraen-3-yl methyl ether R_f 0.62).

Example 26

19-Norpregna-1,3,5(10),7,16-pentaen-20-yn-3-yl methyl ether, 26: To a solution of 19-norpregna-1,3,5(10),7-tetraen-17 β -ol-20-yn-3-yl methyl ether (308.4 mg, 0.9999 mmol) in 2,4-lutidine (2.0 mL, 17 mmol) was added phosphorus oxychloride (0.31 g, 2.0 mmol). After stirring 18 h, the reaction mixture was poured into 35 mL of 3.6 N sulfuric acid and extracted 3 times with 10 mL portions of methylene chloride. The combined organic extracts were washed with 10 mL of 3.6 N sulfuric acid + 10 mL of saturated sodium bicarbonate + 10 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was

washed with 5 mL of methylene chloride and the combined filtrates were concentrated under reduced pressure. The residual dark resin was purified by flash chromatography (5% ethyl acetate/hexanes on silica gel) and preparative
5 TLC (5% ethyl acetate/hexanes), once on silica gel GF (1000 μ) and once on alumina GF (1000 μ), to produce a yellow solid (53.4 mg, 0.184 mmol, 18%).

Example 27

19-Norpregna-1,3,5(10),7,16-pentaen-20-yn-3-yl

10 acetate, 27: To a solution of 19-norpregna-1,3,5(10),7-tetraen-17 β -ol-20-yn-3-yl acetate (672.9 mg, 2.000 mmol) in 2,4-lutidine (4.0 mL, 35 mmol) was added phosphorus oxychloride (0.63 g, 4.1 mmol). After stirring 16 h, the reaction mixture was poured into
15 70 mL of 3.6 N sulfuric acid and extracted three times with 20 mL portions of ether. The combined organic extracts were washed with 40 mL of 3.6 N sulfuric acid + 40 mL of saturated sodium bicarbonate + 40 mL of brine, dried over magnesium sulfate, and filtered through
20 diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography (10% ethyl acetate/hexanes on silica gel) of the resulting foam, followed by crystallization from aqueous ethanol gave
25 slightly yellow needles (327.3 mg, 1.028 mmol, 51%), m.p. 89-94°C. TLC (10% ethyl acetate/hexanes on silica gel) showed product (R_f 0.31; 19-norpregna-1,3,5(10),16-tetraen-3-yl methyl ether R_f 0.64) with contaminants at R_f 0.27, 0.14, 0.04, and 0.00.

30


Example 28

19-Norpregna-1,3,5(10),7,16-pentaen-3-ol-20-yne,

28: To a solution of 19-norpregna-1,3,5(10),7,16-pentaen-20-yn-3-yl acetate (27, 318.4 mg,

1.000 mg) in 50 mL of hot methanol were added 2.4 mL of 5% (w/w) sodium hydroxide. After stirring 1/2 h, 3 mL of 1 N HCl were added and mixture was concentrated under reduced pressure. Preparative TLC (20% ethyl acetate/hexanes on alumina GF, 1000 μ) gave a light yellow resin (91.2 mg, 0.330 mmol, 33%) homogeneous to TLC (20% ethyl acetate/hexanes on silica gel; product R_f 0.36; estral,3,5(10),16-tetraen-3-ol R_f 0.43).

Scheme 8. Syntheses of 19-norpregnenes.



This Sheet Has Been Replaced

THIS SHEET HAS BEEN
REPLACED

Example 29


19-Norpregna-5(10),17-dien-3-one, 29: To a solution of 19-norpregna-2,5(10),17-trien-3-yl methyl ether (422.2 mg, 1.415 mmol) in 45 mL of acetone was
5 added oxalic acid dihydrate (0.49 g, 3.9 mmol) in 7 mL of water. After stirring 7 h, hydrolysis was quenched with the addition of 20 mL of saturated sodium bicarbonate and the mixture was extracted 3 times with 30 mL portions of
10 ether. The combined organic extracts were washed twice with 30 mL portions of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Flash chromatography (10% ethyl acetate/hexanes on silica
15 gel) of the residual film gave a colorless syrup (0.35 g, 1.2 mmol, 87%).

Example 30

19-Norpregna-4,17-dien-10 β -ol-3-one, 30: To a cooled (acetone/dry ice) solution of 19-
20 norpregna-5(10),17-dien-3-one (29, 0.35 g, 1.2 mmol) was added 3-chloroperbenzoic acid (0.89 g, 5.2 mmol) in 9 mL of ether. After stirring 2 h, the reaction was placed in the refrigerator for 18 h. The mixture was then poured into 70 g of 5% (w/w) sodium thiosulfate pentahydrate and
25 the layers were separated. The aqueous layer was extracted 3 times with 15 mL portions of ethyl acetate. The combined organic phases were washed with 15 mL of saturated sodium bicarbonate + 15 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous
30 earth. The residue was washed with 10 mL of ethyl acetate and the combined filtrates were concentrated under reduced pressure. To the residual light yellow solid was added 5% (w/w) potassium hydroxide in methanol (55 mL) and the mixture was refluxed with exclusion of

moisture for 1 h. The reaction was then poured into 140 mL of ice water and extracted with 140 mL of ether. The organic extract was washed twice with 140 mL portions of brine, dried over magnesium sulfate, and filtered through
5 diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. The resulting yellow film was subjected to preparative TLC (50% ethyl acetate/hexanes on silica gel GF, 1000 μ) to give a light yellow foam
10 (84.6 mg, 0.282 mmol, 23%) homogeneous to TLC (50% ethyl acetate/hexanes on silica gel; product R_f 0.26; dehydroepiandrosterone R_f 0.36).

Scheme 9. Synthesis of 19-Norpregna
1,3,5(10), 16-tetraen-3yl methyl ether.



THIS SHEET HAS BEEN
REPLACED

This Sheet Has Been Replaced



Example 31

19-NorPregna-1,3,5(10),16-tetraen-3-ol, 31: To a mixture of 17-iodoestra-1,3,5(10),16-tetraen-3-ol (1.14 g, 3.00 mmol) and

5 [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride monomethylene chloride complex ("Pd(II) catalyst", 61.2 mg, 74.9 μ mol) in tetrahydrofuran (THF, 12 mL) under argon was added triethylborane in THF (1.0 M, 3.3 mL, 3.3 mmol) followed by 15% (w/w) sodium

10 hydroxide (3.0 mL), and the reaction mixture was refluxed for 24 h. After cooling, solvent was removed under reduced pressure, 1 N HCl (12 mL) was added, and the residual suspension was extracted three times with 10 mL aliquots of methylene chloride. The combined organic

15 extracts were washed with 10 mL of saturated sodium bicarbonate + 10 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 5 mL of methylene chloride and the combined filtrates were concentrated under reduced

20 pressure. Flash chromatography (15% ethyl acetate/hexanes on silica gel) with subsequent recrystallization from aqueous methanol gave a white powder (606.2 mg, 2.146 mmol, 72%), m.p. 124-125°C, homogeneous to TLC (15% ethyl acetate/hexanes on silica

25 gel, R_f 0.31; starting material R_f 0.27).

Example 32

19-Norpregna-1,3,5(10),16-tetraen-3-yl methyl ether, 32, from 19-norpregna-1,3,5(10),16-tetraen-3-ol:

30 Potassium carbonate (0.37 g, 2.7 mmol) was added to a solution of 19-norpregna-1,3,5(10),1-tetraen-3-ol (31, 500.0 mg, 1.770 mmol) in acetone (25 mL) and the suspension was heated to reflux with exclusion of moisture. Methyl sulfate (0.42 mL, 4.4 mmol) was added in one portion and the reaction mixture was refluxed with

stirring for 24 h. After cooling, 35 mL of 5% (w/w) sodium hydroxide was added and the mixture was extracted three times with 35 mL aliquots of ether. The combined organic extracts were washed with 35 mL of brine, dried
5 over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of ether and the combined filtrates were concentrated under reduced pressure. Recrystallization from aqueous ethanol gave white needles (476.3 mg, 1.607 mmol, 91%), m.p.
10 97-97.5°C. TLC (1% ethyl acetate/hexanes on silica gel) showed product (R_f 0.1) with traces of a polar contaminant (R_f 0.00). Mixed m.p. and TLC showed this product was identical with product prepared below.




Example 33

15 19-Norpregna-1,3,5(10),16-tetraen-3-yl methyl ether, 33, from 17-iodo-19-norpregna-1,3,5(10),16-tetraen-3-yl methyl ether:
Several different strategies to introduce an alkyl group at C-17 of the estrene nucleus were attempted before
20 finding one which succeeded. As a first attempt, ethyl bromide trapping of incipient 17-lithioestrene from Shapiro elimination (R. Chamberlin, E.L. Liotta, and F.T. Bond, *Org. Syn.*, 1982, 61:141-146) of
estra-1,3,5(10)-triene-17-tosylhydrazone simply gave the
25 17-H compound. Presumably, steric hindrance at the 17-position prevented alkylation and allowed abstraction of hydrogen from ethyl bromide instead. Attempted displacement of iodide from
17-iodoestra-1,3,5(10),16-tetraen-3-ol with alkyl cuprate
30 (E.J. Corey and G.H. Posner, *J. Amer. Chem. Soc.*, 1968, 90:5615-5616) similarly gave the 17-H product, apparently via transmetallation followed by protonolysis. Nickel (II)-catalyzed displacement of iodide using ethyl Grignard (M. Kumada, K. Tamao, and K. Sumitani, *Org.*

Syn., 1978, 58:127-133) likewise failed.

Surprisingly, iodide displacement was effected using palladium (II) catalysis. Earlier workers (G.A. Potter, S.E. Barrie, M. Jarman, and M.G. Rowlands, *J. Med. Chem.*, 1995, 38:2463-2471) were able to show that arylboronates could be used to displace triflate from 17-enol triflates. However, transfer of alkyl groups seemed unlikely given the propensity for intermediate alkylpalladiums to undergo β -elimination. Using ethylborane as alkyl transfer agent iodide was displaced from a variety of 17-iodoestrenes to give the desired 17-alkylestrenes (see schemes 9 and 10). To a mixture of 17-iodo-19-norpregna-1,3,5(10),16-tetraen-3-yl methyl ether (394.3 mg, 1.000 mmol), Pd(II) catalyst (20.4 mg, 25.0 mmol), 3.0 N sodium hydroxide (1.0 mL), and THF under argon was added triethylborane (1.0 M, 1.1 mL, 1.1 mmol). After refluxing 24 h and subsequent cooling, the reaction mixture was extracted with 10 mL of benzene. The organic extract was washed with 10 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 2 mL of benzene and the combined filtrates were concentrated under reduced pressure. Recrystallization from 95% ethanol with charcoal treatment gave tan needles (219.4 mg, 0.7401 mmol, 74%), m.p. 97°C. TLC (10% ethyl acetate/hexanes on silica gel) shows a trace of polar contaminant (R_f 0.00) along with product (R_f 0.62; starting material R_f 0.55).

Scheme 10. Synthesis of 19-Norpregna-1,3,5(10),
7,16-pentaenes.



THIS SHEET HAS BEEN
REPLACED



Example 34

Estra-1,3,5(10),7-tetraene-17-hydrazone, 33: To
equilin (939.4 mg, 3.500 mmol) suspended in 6.6 mL of
abs. ethanol + 1.6 mL (11 mmol) of triethylamine was
5 added 3.1 mL (99 mmol) of hydrazine and the mixture was
refluxed with exclusion of moisture for 1 1/2 h. The
reaction mixture was then added dropwise to 28 mL of
water and the resulting suspension was placed in the
refrigerator overnight. Filtration through a coarse frit
10 and drying under reduced pressure over P_2O_5 gave fine
white crystals (1.0213 g, >100%), m.p. 253-255°C.

Example 35

17-Iodoestra-1,3,5(10),7,16-pentaen-3-ol, 34:
Crude estra-1,3,5(10),7-tetraene-17-hydrazone (1.0058 g,
15 $\leq$ 3.500 mmol) suspended in 21 mL of anh. THF + 4.4 mL
(32 mmol) of triethylamine under argon was cooled in a
water bath and iodine (2.10 g, 16.5 mmol) in 21 mL of
anh. THF was added over 33 min. until color no longer
changed and gas evolution ceased (remaining iodine
20 solution: 5.5 mL). After stirring a further 20 min., the
reaction mixture was concentrated under reduced pressure
and the residue was suspended in 90 mL of ether. The
suspension was washed with 35 mL of 1 N HCl + 35 g of 5%
(w/w) sodium thiosulfate pentahydrate + 35 mL of
25 saturated sodium bicarbonate + 35 mL of brine, dried over
magnesium sulfate, and filtered through diatomaceous
earth. The residue was washed with 10 mL of ether and
the combined filtrates were concentrated under reduced
pressure. Flash chromatography (20 ethyl acetate/hexanes
30 on silica gel) with attempted recrystallization gave a
yellow foam (953.8 mg, 2.522 mmol, 72%).

Example 36

19-Norpregna-1,3,5(10),7,16-pentaen-3-ol, 35: To a mixture of 17-iodoestra-1,3,5(10),7,16-pentaen-3-ol (953.8 mg, 2.522 mmol) and Pd(II) catalyst (51.5 mg, 63.1 μ mol) suspended in 10 mL of THF under argon was added 2.8 mL (2.8 mmol) of 1 M triethylborane + 2.5 mL of 15% (w/w) sodium hydroxide and the mixture was heated to reflux. After heating 24 h, during which time THF apparently boiled off, the cooled residue was suspended in 10 mL of 1 N HCl and extracted three times with 10 mL aliquots of methylene chloride. The combined organic extracts were with 10 mL of saturated sodium bicarbonate + 10 mL of brine, dried over magnesium sulfate, and filtered through diatomaceous earth. The residue was washed with 10 mL of methylene chloride and the combined filtrates were concentrated under reduced pressure. Preparative TLC (20% ethyl acetate/hexanes on silica gel GF, 1000 μ) gave an amber resin (54.4 mg, 0.194 mmol, 7.7%) homogeneous to TLC (20% ethyl acetate/hexanes on silica gel; R_f 0.39; 17-iodoestra-1,3,5(10),16-tetraen-3-ol R_f 0.37).

Example 37

Electrophysiological Studies: The following electrophysiological studies were performed in clinically normal human volunteers of both sexes whose ages ranged from 19 to 29 years. No anesthetics were used, and female subjects were excluded if pregnant.

The stimulation and recording system consists of a "multifunctional miniprobe" described elsewhere (Monti-Bloch, L. and Grosser, B.L. (1991) "Effect of putative pheromones on the electrical activity of the human vomeronasal organ and olfactory epithelium," J. Steroid Biochem. Molec. Biol. 39:573582). The recording electrode is a 0.3 mm silver ball attached to a small (0.1 mm) silver wire insulated with Teflon® the surface

of the electrode is first treated to produce a silver chloride interface, and is then covered with gelatin. It is positioned within a small caliber Teflon® catheter (dia = 5 mm) such that the tip of the electrode protrudes approximately 2 mm. The Teflon® catheter is 10 cm in length and constitutes the terminal extension for a multichannel delivery system which delivers a continuous air stream carrying discreet pulses of chemosensory stimuli. The air stream first passes into a small chamber and is bubbled through a solution containing either a vomeropherin or an olfactant in a diluent or the diluent alone. A solenoid is used to rapidly redirect the air stream from the chamber to a route which bypasses the chamber. This creates a discreet pulse of stimulant in the air stream. A second, outer Teflon® tube with a diameter of 2 mm surrounds the catheter-electrode assemblage, and its central end is connected to an aspirator that provides continuous suction of 3ml/s. This concentric arrangement of the outer suction tube allows the emitted chemosensory stimuli to be localized to an area we call a "minifield" (approx. dia = 1 mm), and it avoids diffusion of substances either to the area outside the intended stimulation site or into the respiratory system. The entire stimulating and recording assemblage may be positioned either on the neurosensory epithelium within the VNO, or on the surface of the olfactory or respiratory epithelium.

Electro-vomeronasogram (EVG): Recordings are carried out in a quiet room with the subject supine; the multi-functional miniprobe is initially stabilized within the nasal cavity using a nasal retractor placed in the vestibule. Reference and ground electrodes consist of silver discs (8 mm), both of which are positioned on the glabella.

The entrance to the VNO, or vomeronasal pit, is

identified by first dilating the nasal aperture and vestibule. A 6x magnifying binocular loupe with halogen illumination is then used to introduce the tip of the Teflon® catheter and recording electrode assemblage into the VNo opening where it is stabilized at an approximate depth of 1 mm within the vomeronasal passage. Optimal placement of the recording electrode is signaled after testing for an adequate depolarization in response to a test substance.

Electrical signals from the recording electrode are fed to a DC amplifier after which they are digitized, computer monitored, and stored. The peak-to-peak amplitude of the signals is measured, and the area under the depolarization wave is integrated, while continuously monitoring the signal both on the computer screen and on a digital oscilloscope. Artifacts produced by respiratory movements are deleted by training the subjects to practice mouth breathing with velopharyngeal closure. Samples of vomeropherins in concentration of 25-800 fmoles are delivered in the continuous air stream for durations from 300 milliseconds to 1 second. Usually, intervals of 3 to 5 minutes separated each series of short test pulses. All components of the lines carrying the test stimuli are made of Teflon®, glass or stainless steel and are carefully cleaned and sterilized before each use. Activity was recorded using standard electroencephalographic (EEG) electrodes placed at positions Cz-A1 and Tz-A1 of the international 10120 system; the ground electrode was placed on the mastoid process. Skin temperature (ST) was recorded by a small (1.0 mm) thermistor probe placed in the right ear lobe. Respiratory frequency (RF) was measured with an adjustable strain gauge placed around the lower thorax. All electrical signals were DC amplified, digitized (MP-100, Biopac systems) and continuously monitored

utilizing a computer.

Statistical Analysis: EVGs, peak-to-peak changes and frequency changes of other parameters were measured and statistically analyzed. The significance of the results was determined by either using paired t-tests or analysis of variance (ANOVA).

Reflex Effects of Vomeroepherins: Studies were conducted to determine the central nervous system (CNS) reflex responses to vomeropherin stimulation of the VNO. The sexually dimorphic local responses induced by vomeropherins were sometimes mirrored in the autonomic response of male & female subjects.

Cortical activity was recorded from Cz and Tz in male and female subjects during application to the VNO of air pulses (300 ms to 1 sec) containing 200 fmoles of vomeropherin. There is also preliminary evidence that the EVG is not associated with trigeminal nociceptor endings since application of a local anesthetic (2% lidocaine) to the respiratory epithelium of the nasal septum neither blocks nor diminishes the EVG (Monti-Bloch, L. and Grosser, B.I. (1991) "Effect of putative pheromones on the electrical activity of the human vomeronasal organ and olfactory epithelium," J. Steroid Biochem. Molec. Biol. 39:573-582.), also, subjects failed to report sensations of pain as a consequence of any of the stimulation procedures.

The following study compares the effect of 23 vomeropherins with 19-norpregnane structure, and placebo (propylene glycol), on autonomic activity and EEG. Twelve healthy human subjects (6 women and 6 men), ages 19 to 29 participated in this study. All substances were delivered airborne to the vomeronasal organ (VNO) puff lasting 5 seconds. For this purpose we use a miniprobe electrode described elsewhere, that allowed local stimulation and simultaneous recording of the organ's

electrovomerogram (EVG). The parameters recorded were: electrodermal activity (EDA), respiratory frequency (RF), electrocardiogram (CF), electromyogram (EMG), body temperature (BT), and EEG from CzA1 and T3A1. Autonomic
5 activity, EEG and EVG were recorded using surface electrodes. All the techniques used were non invasive. The procedure was done in two recording sessions each lasting one hour. The electrical recordings were amplified, digitized, and monitored and stored in a
10 computer. Processing and analysis of the results were done offline.

The data on the tests on the women is shown in FIGS.

3-24, and the data on the men is shown in FIGS. 25-46.

15 The results were summarized in the following tables showing the overall effect of each vomeropherin already subtracted from control. An arbitrary score from 0 to 5 was assigned to compare the activity of the compounds relative to each other, but virtually all of
20 the compounds tested had some effect.

These results show that the effect of some vomeropherins on autonomic activity and EEG is significantly different from placebo. Also shown is that some substances do not have significantly different
25 effects in both genders.

SUMMARY OF EFFECTS OF 19-NOR PREGNANE VOMEROPHERINS ON EEG AND AUTONOMIC ACTIVITY IN WOMEN, n=6

	EVG	EDA	RF	CF	EMG	BT	α -CA	β CA	PERFORMANCE	SCORE
METROL ETHER OF $E2/P2$ +25		+100	-5	-5	0	-2.5	-10	-35	EDA+, RF-, CF-, β -	5
$E2/P2$ +5		-10	-2.5	+10	+5	-2.5	+5	-35	CF+, α +, β -	3
$E2/P2$ +2.5		-10	-2	+5	-5	0	+2.5	-2.5	EDA-, EMG-	3
$E2/P1$ +30		+70	-5	-5	0	0	-5	-2	EDA+ RF- CF-	4
ACETATE OF $E2/P2$ +50		+130	0	0	0	+6	0	-15	EDA+, BT+, β -	4
$E2/P1$ +20		+70	-2.5	-2.5	0	+3	-10	-30	EDA+	2
$E10/P2$ +3		-10	0	+10	-5	0	+10	+10	EDA-, CF+ EMG-, α +	5
$E2/P7$ +25		+50	+5	-5	0	+10	-15	-30	EDA+, BT+	3
$E2/P8$ +25		+30	0	0	0	0	-10	-40	0	0
$E2/P6$ +20		+50	0	-5	0	0	-15	-30	EDA+, CF-	3
$E1/P1$ +45		+110	+5	0	0	0	-5	-10	0	0
$E2/P1$ +40		+95	+3	+5	0	0	0	-15	EDA+, RF+, CF+	4
METROL ETHER OF $E2/P1$ +20		+85	-2.5	-5	0	0	-6	-20	EDA+, CF-	3
$E13/P1$ +1		-10	0	0	-5	0	0	-40	EDA-, EMG-, β -	4
$E8/P1$ +20		-10	0	+5	-2.5	-1	0	-25	0	0
$E5/P1$ 0		-10	0	0	0	0	0	-40	0	0
ACETATE OF $E4/P8$ +2.5		-10	-2.5	+2.5	-5	-3	+10	-20	EMG-, BT-, α +, β -	5
$E2/P8$ +25		+110	0	0	0	+10	+7	-20	EDA+, BT+, α +, β +	5
$E2/P2$ +20		+20	-2.5	-5	0	-2.5	+7	-25	CF-, BT-, α +, β -	5
$E2/P4$ +50		+110	+2.5	0	0	0	+30	-10	EDA+, α +, β -	4
$E12/P8$ +35		+100	0	-5	0	-3	-10	-25	EDA+, CF-, BT-	4
$E6/P1$ +35		+105	+2.5	0	0	-1	-10	-40	0	0


SUMMARY OF EFFECTS OF 19-NOR PREGNANE VOMEROPHERINS ON EEG AND AUTONOMIC ACTIVITY IN MEN, n=6

	EVG	EDA	RF	CF	EMG	BT	α -CA	β CA	PERFORMANCE	SCORE
METHYL ETHER OF E1/P8	+12	+95	0	-5	-2.5	-2.5	+2.5	-10	EDA+, CF-	3(+)
E1/P2	+20	-20	0	+2.5	-2.5	-5	-7	+40	BT-	2
E1/P2	+15	-20	0	+2.5	0	-2.5	-2.5	-20	0	0
E7/M	+18	+70	0	0	0	+7	-2.5	-30	EDA+, BT+, β -	4
ACETATE OF E2/P8	+40	+80	0	0	0	+2.5	-10	-20	EDA+	2
E3/M	+15	+50	0	+2.5	0	-5	-10	-30	EDA+, BT-, β -	4
E8/P2	+20	-20	0	+2.5	-2.5	-1	0	+40	0	0
E2/P7	+30	+120	0	+2.5	0	0	-10	-20	0	0
E2/P5	+10	+90	0	0	0	+10	-5	-30	EDA+, BT+, β -	4
E2/P6	+12	+100	0	0	0	-2.5	0	-20	EDA+	2
E1/M	+35	+120	-2.5	0	0	+2.5	-2.5	-20	EDA+	2
E2/M	+30	+120	0	0	0	-7	-10	-20	EDA+, BT-, (EEG+)	4
METHYL ETHER OF E4/M	+15	+110	-5	0	0	0	0	-20	EDA+, RF-	3
E13/M	+20	-20	0	0	-2.5	0	-5	-15	0	0
E8/M	+18	-20	+2.5	0	0	-2.5	-5	-15	0	0
E5/M	+10	-20	0	-2.5	-2.5	0	-5	-10	0	0
KETONE OF E4/P8	+2.5	-20	0	-2.5	-2.5	-2.5	-5	-15	0	0
E2/P8	+30	+100	0	0	0	0	-10	-20	0	0
E2/P2	+15	+80	0	0	0	+2.5	-5	-25	0	0
E2/P4	+30	+80	-2.5	0	0	-5	-10	-20	EDA+, BT-, (EEG+)	4
E12/P8	+25	+120	0	0	0	+2.5	-10	-25	EDA+	2
E8/M	+30	+130	0	0	0	+2.5	-5	-20	EDA+	2

What is claimed is:

1. A pharmaceutical composition suitable for nasal administration in an individual, said composition comprising an 19-norpregnane steroid and a pharmaceutically acceptable carrier, wherein said steroid has the formula:

This Sheet Has Been Replaced



THIS SHEET HAS BEEN
REPLACED

wherein P₁ is oxo, α- or β-hydroxy, α- or β-acetoxy, α- or β-propionoxy, α- or β-lower alkoxy, α- or β-lower acyloxy or α- or β-benzyloxy;

10 "a", "b", "c", "d", "e", "f", "g", "h", "i", "j",
 "m" and "n" are alternative sites for optional double
 bonds, and "k" may be absent or present with "j" to form
 a triple bond.

P₂ is a hydroxy, hydrogen, lower alkoxy of 1 to 6
15 carbon atoms, or P₂ is absent;

P₃ is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P_4 is methyl or ethyl;

P₅ is hydrogen, methyl or halo;

20 P₆ is hydrogen or methyl'



R' and R" are independently, hydrogen or halo, or are absent.

2. A composition according to Claim 1 wherein "a", "e" and "d" are double bonds.

5 3. A composition according to Claim 2 wherein "h" is a double bond.

4. A composition according to Claim 2 wherein "g" is a double bond.

10 5. A composition according to Claim 4 wherein "n" is a double bond.

6. A composition according to Claim 1 wherein "d" is a double bond.

7. A composition according to Claim 6 wherein "b" is a double bond.

15 8. A composition according to Claim 1 wherein "c" is a double bond.

9. A composition according to Claim 8 wherein "f" is a double bond.

20 10. The pharmaceutical composition of any of Claims 1 through 9 wherein said steroid is dissolved in said carrier.

11. The pharmaceutical composition of any of Claims 1 through 9 wherein said composition is in a liquid form.




12. The pharmaceutical composition of any of Claims 1 through 9 wherein said composition further contains a pharmaceutically acceptable ointment base.

13. The pharmaceutical composition of any of Claims 1 through 9 which contains no more than one of said steroids.

14. The pharmaceutical composition of any of Claims 1 through 9 which contains more than one of said steroids.

15. A method of altering a hypothalamic function of an individual, said method comprising:
providing a 19-nor-pregnane of the formula

This Sheet Has Been Replaced



wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionyloxy, α - or β -lower alkoxy, α - or β -lower acyloxy or α - or β -benzyloxy;
"a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j"



to form a triple bond.

P_2 is a hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P_2 is absent;

P_3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P_4 is methyl or ethyl;

P_5 is hydrogen, methyl or halo;

P_6 is hydrogen or methyl';

R' and R'' are independently, hydrogen or halo, or are absent;


on the surface of nasal neuroepithelial cell of said individual wherein said cell is a part of tissue other than olfactory epithelia; and

administering said 19-nor pregnane derivative within a nasal passage of said individual such that said 19-nor-pregnane derivative binds specifically to said receptor and results in an alteration of hypothalamic function of said individual.

16. A method of altering an autonomic function of an individual, said method comprising:

providing a 19-nor-pregnane of the formula

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED



wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionoxy, α - or β -lower alkoxy, α - or β -lower acyloxy or α - or β -benzyloxy;

"a", "b", "c", "d", "e", "f", "g", "h", "i",
5 "j", "m" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j" to form a triple bond;

P_2 is a hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P_2 is absent;

10 P_3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P_4 is methyl or ethyl;

P_5 is hydrogen, methyl or halo;

P_6 is hydrogen or methyl;

15 R' and R'' are independently, hydrogen or halo, or are absent;

on the surface of nasal neuroepithelial cell of said individual wherein said cell is a part of tissue other than olfactory epithelia; and

20 administering said 19-nor pregnane derivative within a nasal passage of said individual such that said 19-nor-pregnane derivative binds specifically to said receptor and results in an alteration of hypothalamic function of said individual.

25 17. The method of Claim 16 wherein said neuroepithelial cell is located within a vomeronasal organ of said individual.

18. A method according to Claim 17 wherein "a", "e" and "d" are double bonds.

30 19. A method according to Claim 18 wherein "h" is a double bond.



20. A method according to Claim 18 wherein "g" is a double bond.

21. A method according to Claim 20 wherein "n" is a double bond.

5 22. A method according to Claim 17 wherein "d" is a double bond.

23. A method according to Claim 22 wherein "b" is a double bond.

10 24. A method according to Claim 12 wherein "c" is a double bond.

25. A method according to Claim 24 wherein "f" is a double bond.

15 26. The method of any of Claims 15 through 25 wherein the amount of said 19-nor-pregnane derivative that is administered is at least about 100 picograms, but no more than about 100 micrograms.

20 27. The method of Claim 15 wherein the amount of said 19-nor-pregnane derivative that is administered is at least about 1 nanograms, but no more than about 10 micrograms.

28. The method of Claim 27 wherein the amount of said 19-nor-pregnane derivative that is administered is at least about 10 nanograms, but no more than about 1 microgram.

25 29. The method of any of Claims 15 through 25 further comprising preparing a pharmaceutical composition



of said pregnane derivative dissolved in a pharmaceutically acceptable carrier.


30. The method of Claim 29 wherein said pharmaceutical composition is an ointment.

5 31. The method of Claim 29 wherein said pharmaceutical composition is liquid.

32. The method of Claim 29 wherein the administration is by aerosol.

33. The method of Claims 15 through 25 wherein
10 more than one pregnane steroid is administered.

34. A 19-nor-pregnane of the formula



wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionoxy, α - or β -lower alkoxy, α - or β -lower acyloxy or α - or β -benzyloxy;

15 "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j"



to form a triple bond;

P₂ is a hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P₂ is absent;

5 P₃ is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P₄ is methyl or ethyl;

P₅ is hydrogen, methyl or halo;

P₆ is hydrogen or methyl';

10 R' and R" are independently, hydrogen or halo, or are absent;

with the provisos that when P₃ and P₆ are hydrogen, "f", "n", "h" and "g" are absent, P₄ is methyl and R' and R" are not halo, then:

15 i) when P₁ is oxo, "c" is present and P₂ and P₅ are hydrogen, then either of "j" or "i" cannot be present alone, or "m" and "j" cannot be present together, or "i" and "j" cannot be present together, or "m", "j" and "k" cannot be present together, and at least one of "i", "j", "k" or "m" must be present;

20 ii) when P₁ is OH, and "a", "d" and "e" are present, and P₅ is hydrogen, then any of "j", "i", or "m" cannot be present alone, or "j" and "k" cannot be present together, or "i" and "j" cannot be present together, or "m", "j" and "k" cannot be present together, and at least
25 one of "i", "j", "k" and "m" must be present;

iii) when P₁ is beta-OH, "c" is present and P₂ and P₅ are hydrogen, then "i" and "j" cannot be present together, or "m", "j", and "k" cannot be present together;

30 iv) when P₁ is -OMe, "d" and "b" are present, then either of "j" and "i" cannot be present alone;

v) when P₁ is oxo, "d" is present, and P₅ is hydrogen, "i" cannot be present alone or "j" and "k"
35 cannot be present together.



35. A method of alkylating a steroid having a 17-halo-16-ene D-ring comprising the step of contacting said steroid with trialkylborane in the presence of a catalytic amount of Pd(II), to produce a 17-alkyl-16-ene steroid product.

36. A method according to Claim 35 wherein said steroid comprises a 17-iodo-16-ene D-ring.

37. A method according to Claim 35 wherein said alkyl group contains 1-6 carbon atoms.

38. A method according to Claim 37 wherein said alkyl group comprises the ethyl group.

39. The compound according to Claim 34, 19-norpregna-4,20-dien-3 β -ol.

40. The compound according to Claim 34, 19-norpregna-1,3,5(10),16,20-pentaen-3-ol.

41. The compound according to Claim 34, 19-norpregna-5-(10),20-dien-3-one.

42. The compound according to Claim 34, 19-norpregna-5(10),20-dien-3-ol.

43. The compound according to Claim 34, 19-norpregna-4,20-dien-10 β -ol-3-one.

44. The compound according to Claim 34, 19-norpregna-4,9(10),20-trien-3-one.



45. The compound according to Claim 34, 19-norpregn-1,3,5(10),16-tetraene-6-one-20-yn-3-yl acetate.

46. The compound according to Claim 34, 19-norpregna-1,3,5(10),16-tetraene-3,6 β -diol-20-yne.

47. The compound according to Claim 34, 19-norpregna-1,3,5(10),17-tetraene-3-ol.

48. The compound according to Claim 34, 19-norpregna-1,3,5(10),6,17-pentaen-3-ol.

49. The compound according to Claim 34, 19-norpregna-1,3,5(10),6,8,17-hexaen-3-ol.

50. The compound according to Claim 34, 19-norpregna-1,3,5(10),7,16-pentaen-3-ol.

51. The compound according to Claim 34, 19-norpregna-2,5(10),16-trien-3-yl methyl ether.

52. The compound according to Claim 34, 19-norpregna-4,16-dien-3-one.

53. The compound according to Claim 34, 19-norpregna-5(10),16-dien-3-one.

54. The compound according to Claim 34, 19-norpregna-4,16-dien-10 β -ol-3-one.



WO 96/40727

PCT/US96/09665




55. The compound according to Claim 34, 19-norpregna-2-5(10)-dien-3-yl methyl ether.

56. The compound according to Claim 34, 19-norpregna-5(10),-en-3-one.

57. The compound according to Claim 34, 19-norpregna-4-en-10 β -ol-3-one.

58. The compound according to Claim 34, 19-norpregna-4,17-dien-10 β -ol-3-one.

1/16

**FIG. 1.****FIG. 2.****FIG. 3.**

2/16




FIG. 4.




FIG. 5.







FIG. 6.

3/16

**FIG. 7.****FIG. 8.****FIG. 9.**

4/16




FIG. 10.




FIG. 11.




FIG. 12.

5/16




FIG. 13.




FIG. 14.







FIG. 15.

*FIG. 16.**FIG. 17.**FIG. 18.*




FIG. 19.




FIG. 20.




FIG. 21.

8/16




FIG. 22.




FIG. 23.










FIG. 24.

9/16

**FIG. 25.****FIG. 26.****FIG. 27.**

10/16

**FIG. 28.****FIG. 29.****FIG. 30.**

11/16




FIG. 31.




FIG. 32.










FIG. 33.

**FIG. 34.****FIG. 35.****FIG. 36.**

**FIG. 37.****FIG. 38.****FIG. 39.**

14/16




FIG. 40.




FIG. 41.




FIG. 42.

15/16




FIG. 43.




FIG. 44.







FIG. 45.

16/16

**FIG. 46.**



"Sexually dimorphic" refers to a difference in the effect of, or response to, a pharmaceutical agent between males and females of the same species.


An "effective amount" of a drug is a range of quantity and/or concentration which brings about a desired physiological and/or psychological effect when administered to an individual in need of the drug. In the present case, a needy individual is one with a physiological or behavioral trait which is normally regulated by the hypothalamus and wherein it is desirable to affect the function of the hypothalamus or the trait. The effective amount of a given drug may vary depending upon the function to be affected, the desired effect, route of administration, and the like. For example, when the steroid is administered as a solution applied to the facial skin of a subject an effective concentration is from 1 microgram/ml to 100 μ g/ml, preferably 10 to 50 μ g/ml and most preferably 20 to 30 μ g/ml. When the steroid is introduced directly into the VNo an effective amount is about 1 picogram to about 1 nanogram, more preferably about 10 picograms to about 50 picograms. When the steroid is administered to the nasal passage, by ointment, cream or aerosol, or the like, an effective amount is about 100 pg to about 100 micrograms, preferably about 1 ng to about 10 micrograms. It follows that some drugs may be effective when administered by some routes, but not effective when administered by other routes.

The "hypothalamus" is the portion of the diencephalon comprising the ventral wall of the third

06 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997

providing a pharmaceutical composition suitable for nasal administration in an individual. The composition contains a pharmaceutically acceptable carrier and a pregnane steroid with the formula:




















































- 5 wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionyloxy, α - or β -lower acetoxy, α - or β -lower acyloxy, or α - or β -benzyloxy;
 "a", "b", "c", "d", "e", "f", "g", "h", "i", "j",
 "m" and "n" are alternative sites for optional double
 10 bonds, and "k" may be absent or present with "j" to form
 a triple bond;
 P_2 is hydroxy, hydrogen, lower alkoxy of 1 to 6
 carbon atoms, or P_2 is absent;
 P_3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6
 15 carbon atoms or halo;
 P_4 is methyl or ethyl;
 P_5 is hydrogen, methyl or halo;
 P_6 is hydrogen or methyl.

- One class of preferred steroid compositions
 20 contain steroids wherein "d" is a double bond, and
 optionally "b" is present as a double bond. Another
 preferred class has "a", "d" and "e" present, and g or h
 are optionally present. If "g" is present in this case,

06 JAN 1997








































PCT/US 96/09665
IPEA/US 06 JAN 1997

19-NORPREGNANES

P E	1	2	3	4	5	6	7	8
1	 KNOWN	 KNOWN	 NOVEL	 KNOWN	 KNOWN	 KNOWN	 KNOWN	 KNOWN
2	 KNOWN	 KNOWN	 KNOWN	 KNOWN	 NOVEL	 NOVEL	 KNOWN	 KNOWN
3	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 KNOWN	 KNOWN
4	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
5	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
6	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
7	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL

05 JAN 1977


PCT/US 96/09665
IPEA/US 06 JAN 1997

E/P								
	1	2	3	4	5	6	7	8
8	 KNOWN	 KNOWN	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
9	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
10	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
11	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
12	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL	 NOVEL
13	 NOVEL	 KNOWN	 NOVEL	 NOVEL	 KNOWN	 NOVEL	 NOVEL	 NOVEL


06 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997

U.S. Patent 3,492,318 teaches preparation of 7 α , 18, and 21-methyl analogs.



21-methyl analog:




L.A. Van Dijck, B.J. Lankwerden, J.G.C.M. Vermeer, and
5 A.J.M. Weber, *Recl. Trav. Chim. Pays-Bas Belg.*, 1971, 90,
801.

06 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997


Scheme 1. Syntheses of 19-norpregnanes.



06 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997


Scheme 2. Syntheses of further norpregnanes.






05 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997


Scheme 3. Further syntheses of norpregnanes.



Scheme 4. 17-Ethylenation of ketones.




Scheme 5. Pd(II)-catalyzed synthesis of 19-norpregnenes.



06 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997


Scheme 6. Synthesis of 19-norpregnanes.



06 JAN 1997

PCT/US 96/09665
IPEA/US 06 JAN 1997


Scheme 7. Additional syntheses of 19-norpregnenes.



06 JAN 1997

PCT/US 96/09666!
IPEA/US 06 JAN 1997


Scheme 8. Syntheses of 19-norpregnenes.



REPLACEMENT SHEET

06 JAN 1997


Scheme 9. Synthesis of 19-Norpregna
1,3,5(10), 16-tetraen-3yl methyl ether.




06 JAN 1997

PCT/US 96/0966
IPEA/US 06 JAN 1997

Scheme 10. Synthesis of 19-Norpregna-1,3,5(10),
7,16-pentaenes.






PCT/US 96/0966!
IDEA/US 06 JAN 1997

What is claimed is:

1. A pharmaceutical composition suitable for nasal administration in an individual, said composition comprising an 19-norpregnane steroid and a
- 5 pharmaceutically acceptable carrier, wherein said steroid has the formula:



wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionoxy, α - or β -lower alkoxy, α - or β -lower acyloxy or α - or β -benzyloxy;

10 "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j" to form a triple bond.

P_2 is a hydroxy, hydrogen, lower alkoxy of 1 to 6
15 carbon atoms, or P_2 is absent;

P_3 is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P_4 is methyl or ethyl;

P_5 is hydrogen, methyl or halo;

20 P_6 is hydrogen or methyl'




12. The pharmaceutical composition of any of Claims 1 through 9 wherein said composition further contains a pharmaceutically acceptable ointment base.


13. The pharmaceutical composition of any of Claims 1 through 9 which contains no more than one of said steroids.

14. The pharmaceutical composition of any of Claims 1 through 9 which contains more than one of said steroids.

15. A method of altering a hypothalamic function of an individual, said method comprising:
providing a 19-nor-pregnane of the formula



wherein P_1 is oxo, α - or β -hydroxy, α - or β -acetoxy, α - or β -propionoxy, α - or β -lower alkoxy, α - or β -lower acyloxy or α - or β -benzyloxy;
"a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "m" and "n" are alternative sites for optional double bonds, and "k" may be absent or present with "j"



PCT/US 96/09666E
IPEA/US 06 JAN 1997

to form a triple bond.

P₂ is a hydroxy, hydrogen, lower alkoxy of 1 to 6 carbon atoms, or P₂ is absent;

5 P₃ is oxo, hydrogen, hydroxy, lower alkoxy of 1-6 carbon atoms or halo;

P₄ is methyl or ethyl;

P₅ is hydrogen, methyl or halo;

P₆ is hydrogen or methyl';


10 R' and R'' are independently, hydrogen or halo, or are absent;


on the surface of nasal neuroepithelial cell of said individual wherein said cell is a part of tissue other than olfactory epithelia; and

15 administering said 19-nor pregnane derivative within a nasal passage of said individual such that said 19-nor-pregnane derivative binds specifically to said receptor and results in an alteration of hypothalamic function of said individual.

20 16. A method of altering an autonomic function of an individual, said method comprising:

providing a 19-nor-pregnane of the formula





PCT/US 96/09665
IPEA/US 06 JAN 1997


30. The method of Claim 29 wherein said pharmaceutical composition is an ointment.

5 31. The method of Claim 29 wherein said
pharmaceutical composition is liquid.

32. The method of Claim 29 wherein the administration is by aerosol.

33. The method of Claims 15 through 25 wherein
10 more than one pregnane steroid is administered.

34. A 19-nor-pregnane of the formula



wherein P₁ is oxo, α- or β-hydroxy, α- or β-acetoxy, α- or β-propionoxy, α- or β-lower alkoxy, α- or β-lower acyloxy or α- or β-benzyloxy;

15 "a", "b", "c", "d", "e", "f", "g", "h", "i",
 "j", "m" and "n" are alternative sites for optional
 double bonds, and "k" may be absent or present with "j"

**CORRECTED
VERSION***

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07J 9/00, 41/00, 5/00, 7/00, A61K 31/56	A1	(11) International Publication Number: WO 96/40727 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09665 (22) International Filing Date: 7 June 1996 (07.06.96) (30) Priority Data: 08/485,615 7 June 1995 (07.06.95) US (71) Applicant: PHERIN CORPORATION [US/US]; Suite 240, 535 Middlefield Road, Menlo Park, CA 94025-3444 (US). (72) Inventors: JENNINGS-WHITE, Clive, L.; 3096 South 2300 East, Salt Lake City, UT 84109 (US). BERLINER, David, L.; 380 Shelby Lane, Atherton, CA 94027 (US). ADAMS, Nathan, William; 4858 South Rockhill Lane, Salt Lake City, UT 84123 (US). (74) Agent: SUYAT, Reginald, J.; Fish & Richardson P.C., 2200 Sand Hill Road, Menlo Park, CA 94025 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: NOVEL NOR-PREGNANES FOR INDUCING HYPOTHALAMIC EFFECTS (57) Abstract The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor-pregnane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.		